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Dying Tt Save Your Colon? Changing the Way We Look at Ulcerative Colitis
Abstract
Treatment options for mesalamine-refractory ulcerative colitis (UC) include chronic immunosuppressive
medications or colectomy surgery. Current treatment paradigms presume the patients' foremost desire is
to avoid surgery and therefore view surgery as a consequence of medication failure. However,
immunosuppressive therapy may not be ideal for all patients due to unclear durable efficacy and potential
lethal serious adverse events (SAEs). We sought to quantify UC patients' risk tolerance of chronic
immunosuppression to avoid colectomy.
We first conducted a meta-analysis of all-cause and cause-specific mortality in both Crohn's disease (CD)
and UC, and examined the effect of study design on this outcome. We found elevated all-cause and
cause-specific mortality in both UC and CD including colorectal-, pulmonary- and non-alcoholic liver
disease-related relative mortality. We further found little evidence that study design impacted all-cause
relative mortality summary estimates.
We next conducted a study examining the reliability of the 6-Point Mayo score, a simple two-item noninvasive non-physician driven index, for measuring UC disease activity. We found the 6-Point Mayo to
strongly correlate with more extensive disease assessment tools, with a similar sensitivity, specificity and
ROC area under the curve for patient-defined clinical remission.
With these insights, we conducted a discrete choice experiment to quantify the UC patients' mean
maximum acceptable risk for life-threatening SAEs associated with immunosuppressant therapy to avoid
colectomy surgery with various outcomes. We found that UC patient tolerance for medical and surgical
risks do not conform to conventional preference-elicitation methodology assumptions. UC patients were
willing to accept very high levels of fatal SAEs to avoid an ostomy. However, if a durable medicationinduced remission could not be achieved, patients were equally satisfied with J-pouch surgery. Several
important clinical phenotypes impacted patient risk tolerances. This is the first empirical demonstration
that UC patients view a well-functioning J-pouch as equivalent to mild clinical disease. It further
demonstrates that patients value medication efficacy and suggests that clinical remission, rather than
response, be the preferred outcome for therapy trials and treatment algorithms. Our findings underline the
need for rigorous methodologies to accurately measure patient-preferences; and suggest potential
avenues to enhance UC patient autonomy and facilitate shared decision-making.
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ABSTRACT
WHAT IS YOUR COLON WORTH TO YOU? CHANGING THE WAY WE LOOK AT
ULCERATIVE COLITIS
Meenakshi Bewtra
James D. Lewis
Treatment options for mesalamine-refractory ulcerative colitis (UC) include
chronic immunosuppressive medications or colectomy surgery. Current treatment
paradigms presume the patients’ foremost desire is to avoid surgery and therefore view
surgery as a consequence of medication failure. However, immunosuppressive therapy
may not be ideal for all patients due to unclear durable efficacy and potential lethal
serious adverse events (SAEs). We sought to quantify UC patients’ risk tolerance of
chronic immunosuppression to avoid colectomy.
We first conducted a meta-analysis of all-cause and cause-specific mortality in
both Crohn’s disease (CD) and UC, and examined the effect of study design on this
outcome. We found elevated all-cause and cause-specific mortality in both UC and CD
including colorectal-, pulmonary- and non-alcoholic liver disease-related relative
mortality. We further found little evidence that study design impacted all-cause relative
mortality summary estimates.
We next conducted a study examining the reliability of the 6-Point Mayo score, a
simple two-item non-invasive non-physician driven index, for measuring UC disease
activity. We found the 6-Point Mayo to strongly correlate with more extensive disease
assessment tools, with a similar sensitivity, specificity and ROC area under the curve for
patient-defined clinical remission.
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With these insights, we conducted a discrete choice experiment to quantify the
UC patients’ mean maximum acceptable risk for life-threatening SAEs associated with
immunosuppressant therapy to avoid colectomy surgery with various outcomes. We
found that UC patient tolerance for medical and surgical risks do not conform to
conventional preference-elicitation methodology assumptions. UC patients were willing
to accept very high levels of fatal SAEs to avoid an ostomy. However, if a durable
medication-induced remission could not be achieved, patients were equally satisfied with
J-pouch surgery. Several important clinical phenotypes impacted patient risk
tolerances. This is the first empirical demonstration that UC patients view a wellfunctioning J-pouch as equivalent to mild clinical disease. It further demonstrates that
patients value medication efficacy and suggests that clinical remission, rather than
response, be the preferred outcome for therapy trials and treatment algorithms. Our
findings underline the need for rigorous methodologies to accurately measure patientpreferences; and suggest potential avenues to enhance UC patient autonomy and
facilitate shared decision-making.

v

TABLE OF CONTENTS

ABSTRACT ............................................................................................................................... IV
LIST OF TABLES ................................................................................................................. VIII
LIST OF ILLUSTRATIONS ................................................................................................... IX
INTRODUCTION ....................................................................................................................... 1
Overview of Ulcerative Colitis ........................................................................................................... 1
Surgical Treatment in Ulcerative Colitis .......................................................................................... 1
Risks of Surgical Treatment in Ulcerative Colitis .......................................................................... 2
Medical Treatment in Ulcerative Colitis ........................................................................................... 2
Risks of Medical Treatment in Ulcerative Colitis ........................................................................... 3
Overview of Decision Making in Ulcerative Colitis ........................................................................ 6
Time Trade-Off and Standard-Gamble Studies in Ulcerative Colitis .......................................... 7
Limitations of Time Trade-Off and Standard-Gamble Studies in Ulcerative Colitis ................ 8
Discrete Choice Experiments ............................................................................................................ 9
Advantages of Discrete Choice Experiments ............................................................................... 10
Summary ............................................................................................................................................. 11

CHAPTER 2: CROHN’S DISEASE AND ULCERATIVE COLITIS ARE
ASSOCIATED WITH ELEVATED STANDARDIZED MORTALITY RATIOS: A
META-ANALYSIS ................................................................................................................... 15
CHAPTER 3: PATIENT-DRIVEN SIX-POINT MAYO SCORE CORRELATES
WITH DISEASE INDICES AND PATIENT-DEFINED REMISSION IN
ULCERATIVE COLITIS ........................................................................................................ 44
CHAPTER 4: PATIENT-PREFERENCES FOR SURGICAL VERSUS MEDICAL
THERAPY IN ULCERATIVE COLITIS ............................................................................. 70
vi

CONCLUSIONS ...................................................................................................................... 98

vii

LIST OF TABLES
Table 2.1: Prior meta-analyses of IBD mortality……………………………………………19
Table 2.2: Studies included in meta-analysis………………………………………......24-25
Table 2.3: Standardized Mortality Ratios……………………………………………………26
Table 2.4: All-Cause Standardized Mortality Ratios……………………………………27-28
Table 2.5: Cause-specific Standardized Mortality Estimates……………………...….32-37
Table 2.6: Table of included diagnoses (ICD codes) for cause-specific mortality……...37
Table 3.1: Components of the SCCAI, 6-Point Mayo and single patient-driven disease
activity question…………………………………………………………………………………49
Table 3.2: Summary of Patient Characteristics…………………………………………….53
Table 3.3: Results of Disease Severity Indices in Initial Study Population………...……54
Table 3.4: Comparison of ROC area under the curve generated by addition of SCCAI
components to the 6-Point Mayo predicting patient-defined remission…………………..59
Table 3.5: Summary of Patient Characteristics in Validation Study Cohort……………..60
Table 3.6: Results of Disease Severity Indices in Validation Study Population……...…61
Table 3.7: Comparison of ROC area under the curve generated by the addition of
SCCAI components to the 6-Point Mayo predicting patient-defined remission in the
validation cohort………………………………………………………………………………...64
Table 4.1: Treatment Attributes and Levels………………………………………………...77
Table 4.2: Summary of Patient Characteristics…………………………………………84-85
Table 4.3: Maximum Acceptable 10-Year Serious Adverse Event Risk (MAR) for
Selected Treatment Benefits to Avoid Surgery……………………………………………..88

viii

LIST OF ILLUSTRATIONS
Figure 1.1: Conceptual model for development of thesis studies………………………...12
Figure 2.1: Identification of Studies for Meta-Analysis…………………………………….21
Figure 2.2: Standardized Mortality Ratios for UC and CD………………………………...29
Figure 2.3: Cumulative Meta-Analysis of All-Cause Mortality…………………………….31
Figure 3.1: Identification of Initial Study Patient Population………………………………51
Figure 3.2A: Evaluation of patients in a 6-Point Mayo……………………………………..55
Figure 3.2B: Evaluation of patients in remission as defined by a single Likert-scale of
patient-defined disease activity……………………………………………………………….55
Figure 3.3A: ROC Curves for Single Question Remission………………………………..57
Figure 3.3B: ROC Curves for Single Question Remission Among Patients Exposed to
Immunosuppressants…………………………………………………………………………..57
Figure 3.4: ROC Curves for Single Question Remission, Validation Study……………..63
Figure 3.5: ROC Curves for UC Endoscopic Index of Severity in the Validation Study..65
Figure 4.1: Example of conjoint scenario comparing medication and surgical therapy for
UC flare………………………………………………………………………………………….79
Figure 4.2: Identification of Final Patient Population………………………………………83
Figure 4.3A: Preference weights for varying levels of mortality from lymphoma or
serious infection over 10 years………………………………………………………………..87
Figure 4.3B: Relative preference utility for risk attributes and medication efficacy…….87
Figure 4.4: Subgroup analysis of preference utility ratios…………………………………90

ix

INTRODUCTION

Overview of Ulcerative Colitis
UC is a chronic relapsing remitting form of inflammatory bowel disease (IBD) with
no known medical cure. UC affects over a half a million people in the United States
alone and is rising in both incidence and prevalence.1 Patients with UC have
inflammatory disease limited to their colon. Disease activity can result in diarrhea,
abdominal pain, anemia, fatigue, and other systemic symptoms. Disease activity can
range from remission (no symptoms) to moderate-severe (more than six bloody bowel
movements a day with fevers, increased heart rate, and anemia) or even fulminant
disease (more than ten bloody bowel movements a day, passage of blood alone from
the rectum, anemia requiring blood transfusions, and severe abdominal pain). These
patients are additionally at risk for developing dilation of their colon that can result in
perforation, with an extremely high morbidity and mortality.1-3 UC predominantly affects
young adults in the 2nd and 3rd decade of life, resulting in significant economic burden
from both chronic treatment and lost productivity.
Surgical Treatment in Ulcerative Colitis
UC patients are in a unique position because disease is limited to the colon;
therefore surgery, specifically total proctocolectomy, provides a surgical “cure.” The two
most common operations performed for UC are total proctocolectomy with end ileostomy
and restorative ileal pouch anal anastomsosis (IPAA). The former entails a permanent
ileostomy while the latter avoids this, but is associated with frequent bowel movements,
the risk of pouchitis and the risk of fecal incontinence.
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Risks of Surgical Treatment in Ulcerative Colitis
Surgery has its own risks4-6; and quality of life following surgery is not perfect.
Those having total proctocolectomy with end ileostomy will have a permanent external
draining ileostomy. Those having IPAA surgery still have six bowel movements a day on
average. This means that some patients will have more bowel movements than prior to
their colectomy. Additionally, patients with IPAA surgery are at risk for having fecal
incontinence.
Reported rates of serious infectious complications (including septic
complications, pelvic abscesses and wound dehiscence) range from 1%-10% and may
be institution and procedure-dependent, and related to pre-operative medication
exposure (including corticosteroid use).4,6,7 Mortality rates with elective colectomy range
are no higher than 1% at 35 months; and as low as 0.5% at 33 months.3-6
Medical Treatment in Ulcerative Colitis
Mesalamine (5-ASA) has proven to be a safe and effective therapy for UC.
However, 5-ASA fails to induce a clinical remission in 50% or more of UC patients.8-14
For patients in whom 5-ASA therapy is inadequate to control their disease,
corticosteroids are frequently used. Unfortunately, over 50% of patients either will suffer
disease recurrence upon discontinuation of corticosteroids, or will be unable to taper off
corticosteroids at all due to recurrent disease at lower doses of the drug.15 Therefore,
alternatives to corticosteroid therapy have been developed. Cyclosporine and
tacrolimus have also been used as a bridge to immunomodulator therapy for refractory
UC, particularly in patients who have failed to respond to intravenous corticosteroids.16,17
Immunomodulators include the medications 6-mercaptopurine (6-MP) and its prodrug
azathioprine. These are thiopurine analogs that modulate the immune response by
2

inhibiting both T- and B-cell lymphocytes, interfering with natural killer cells, and
inhibiting suppressor T-cell function and cell-mediated immunity18. An alternative to the
thiopurines include the anti-TNF medications including the medication infliximab, a
chimeric monoclonal antibody that is 75% human and 25% murine19. Infliximab targets
tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine that plays a central
role in the initiation and promotion of the inflammatory cascade, and is a key mediator in
several disease states including endotoxin-induced sepsis, rheumatoid arthritis, and the
cachexia associated with malignancy. Infliximab is approved by the FDA for treatment of
UC. Several other anti-TNF medications have more recently been approved or will likely
be approved for UC, including adalimumab and golimumab (fully human monoclonal
antibodies to TNF-α), and certolizumab pegol (a PEGylated Fab antibody fragment to
TNF-α).
Risks of Medical Treatment in Ulcerative Colitis
While corticosteroids have been the mainstay of therapy for UC patients with
disease flares, corticosteroids are associated with numerous well-characterized side
effects with long-term use including near inevitable occurrence of bone disease and
cataracts. Corticosteroids have been associated with a 2-3 times increased odds of
infection, including post-operative infections, serious infections and opportunistic
infections.20-22 Finally, corticosteroids have been associated with an increased mortality
risk.20,23
Both the thiopurine analogs and anti-TNF medications suppress the immune
system and modulate the inflammatory system in an attempt to reduce inflammatory
activity in the colon and prevent relapses. Because of the chronic nature of UC, these
medications are for long-term use. For those not pursuing definitive surgical treatment,
3

usage of these medications typically is planned for an indefinite duration. Rates of
infection for those on thiopurine analogs and anti-TNF therapy are as high as 5% per
year.21,24-26 The thiopurine analogs and anti-TNF therapies also may increase the risk of
certain cancers including an increased risk of cervical dysplasia and non-melanoma skin
cancer.27-29

The risk of lymphoma associated with thiopurine analogs and anti-TNF use

that may be as much as four times that of the general population; with combination
therapy, this risk increases to 6-10 times that of the general population.30-33 A
particularly aggressive and nearly universally fatal form of lymphoma, called
hepatosplenic T-cell lymphoma (HSTCL), is associated with immunosuppression,
particularly in young adults.34-36

By virtue of retaining their colon, IBD patients also

have a lifetime risk of colon cancer that is as high as three times that of the general
population. 37
Despite this, UC patients treated with medical therapy were believed to have a
normal life expectancy. However, two recent studies question that assumption. In a
study by Roberts et al. examining patients who were admitted to the hospital in England
for their UC, those patients pursuing chronic medical therapy had a two-times increased
odds of mortality compared to those pursuing an elective colectomy surgery over the
ensuing three years.38 A similar record-linkage study in Scotland found that those
patients pursuing an elective colectomy had a significantly improved survival compared
to those admitted emergently to the hospital for their UC, even after adjustment for age,
gender and comorbidity status.39
Additionally, as with any medical therapies, there is the risk of medication failure
with thiopurine analogs and anti-TNF’s. In randomized-controlled trials of the thiopurine
analogs for induction of remission for UC, there was no difference between the drugs
4

and placebo or mesalamine.18,40 In contrast, they have been shown to be effective as
steroid sparing agents and in the maintenance of remission in ulcerative colitis, although
in placebo-controlled studies, 36% failed to maintain remission at one year.18
Several clinical trials have evaluated the efficacy of infliximab in UC. The two
largest, Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively),
evaluated the efficacy of infliximab for induction and maintenance of disease remission
in UC. In ACT 1, 69.4% of patients receiving 5mg/kg infliximab achieved and maintained
remission at week 30, with similar findings reproduced in the ACT 2 trial.41
Based upon these studies, at least one-third of patients who start
immunomodulators or anti-TNFs will fail either induction or maintenance of remission.
The consequences of incompletely treated disease as a result of medication failure are
poorly understood. However, indirect evidence suggests that these patients are at
increased risk of morbidity and mortality. In some, active UC can progress to severe or
fulminant disease, and rarely perforation of the colon. Therefore, these patients are at
an increased risk of death from uncontrolled disease alone. Patients who require an
emergent colectomy have an immediate post-operative mortality rate between 0.6% and
7.4%.3,42-44 Recently, in a sample representative of the U.S., it was shown that emergent
colectomy had a substantially higher mortality rate than elective colectomy for UC. In
this study, the overall in-hospital mortality rate for UC patients undergoing an elective
total abdominal colectomy was 0.7%; however, for those who had a colectomy following
an emergent or urgent admission, the mortality rate was as high as 7.4%.3 Similarly, in a
comparison of elective and emergent colectomy surgery in Britain, mortality rates three
years after emergent colectomy were 13.2% compared to 3.7% for elective colectomy
(adjusted odds ratio 3.04, p<0.001).38
5

Overview of Decision Making in Ulcerative Colitis
If surgery for UC resulted in a completely normal quality of life, the choice
between medical and surgical therapy would be obvious. Because this is not the case,
physicians and their patients have traditionally accepted the risks of medical therapies
and considered surgery an option of “last resort.” At a national level, while
immunosuppressant and prolonged corticosteroid use in UC has increased, surgical
rates have not changed significantly over the past several decades or may be
decreasing.45-47 The algorithm of making colectomy surgery the product of medication
failure rests on the presumption that the patient’s foremost desire is to avoid surgery.
However, for some patients, chronic immunosuppressive therapy may not be ideal due
to unclear durable efficacy and potential lethal serious adverse events (SAEs).
Because all potential therapies (medical and surgical) have potential risks and
benefits, and thus implications for patient quantity and quality of life, patient collaboration
in decision-making is essential. The last few decades have seen an increased
importance placed on patient preferences in healthcare.48,49 Patient preferences
arguably play a critical role in health care outcomes, and an increasing premium is being
placed on patient autonomy and shared decision-making: patients’ preferences for
therapies influence adherence, compliance and satisfaction with therapies, which in turn
influences overall care. In turn, understanding patient preferences for risks and benefits
of therapies can inform physicians in their daily interaction with patients; regulators in
setting thresholds for therapy efficacy and risk; and national organizations in setting
treatment guidelines. Thus, rigorous methodologies capable of accurately quantifying
patient preferences in large patient populations are needed to include UC patients’
voices in an increasingly complex decision process regarding their care.
6

Time Trade-Off and Standard-Gamble Studies in Ulcerative Colitis
Health-state utility is a well-known cardinal index of the quality of a given health
state. Utilities can be measured at population or individual levels, and vary as people’s
health changes. Changes in health states can be expressed as incremental utility elicited
by either time-tradeoff or standard-gamble question formats. Utilities can be converted
to quality-adjusted life years (QALYs) that are used in cost-utility analysis. QALYs weight
durations in each health state by the average utility of that state and facilitate healthoutcome comparisons across groups of people, health outcomes and durations.
In time-trade-off (TTO) studies, respondents evaluate specific treatment-outcome
scenarios and are asked how much of a reduction in expected life years they would
accept for living in perfect health instead of living the rest of their expected lifetime in the
compromised health state. Health-state utility is measured as the ratio of equivalent
years in perfect health to years in compromised health.
Standard-gamble (SG) studies elicit the highest level of risk of the worst
imaginable health state (usually assumed to be death) respondents would accept in
return for best possible health. Setting the utility of death at zero and the utility of best
possible health at 1, and assuming that expected utility is the sum of outcomes weighted
by probabilities, one minus the indicated risk of death indicates the health-state utility.
A number of TTO and SG studies have evaluated preferences of UC patients for
continued medical management of UC versus colectomy surgery.50-54 Overall, these
studies suggest that UC patients view colectomy surgery and the post-surgery state with
significantly diminished quality of life, thus supporting current treatment algorithms of
making colectomy surgery an option of last resort. However, at least one of these
studies found that optimal utility (used in Markov modeling for various treatment
7

decisions) was highly variable among UC patients with total colectomy being the optimal
treatment choice for 37% of their patient sample. When utilizing the average utility for
analysis, medical therapy was superior to colectomy surgery. However, this substantial
variability in utilities was reflected in their sensitivity analysis, in which only one-third of
patients had highly reliable optimal treatment decisions in modeling.50
Limitations of Time Trade-Off and Standard-Gamble Studies in Ulcerative Colitis
Using traditional methods such as TTG and SG to obtain utility values for QALY
estimation has been widely accepted for health-technology assessment because these
methods allow for a simple method of integrating mortality, morbidity and preferences for
therapies into a single estimation representing the equivalent years of perfect health.
This allows for relatively simple comparisons with other QALY-based measurements
(including some quality of life questionnaires) and utilization of these QALYs for costutility analyses.
However, it is this simplicity that can become problematic due to inaccurate
assumptions regarding patient preferences. TTO and SG studies suffer from a number
of fundamental limitations that have been recognized for several decades.55-59 The
clinically-artificial method of eliciting patient utilities in TTO/SG studies employs cardinalutility, a ratio-scale metric rejected by nineteenth-century utility theorists in favor of
ordinal-utility measures. Ordinal utility is the basis of virtually all subsequent appliedeconomics research.60
Numerous validity tests of QALY studies also have rejected the assumptions of
independence, procedural and description invariance, linearity over time and
comparability across groups of patients.61,62 Furthermore, in the interest of simplicity,
8

conventional TTO and SG applications assume that health history or current health state
do not affect relative preferences. Moreover, conventional health-state utility
measurement techniques are unable to capture the impact of acute conditions, treatment
risks, or process-related factors such as the method of administration or treatment
duration. Such factors can play a significant role in understanding UC patients’
preferences for treatments.
Discrete Choice Experiments
Discrete choice experiments (DCEs; also known as choice-format conjoint
analysis) employ a multi-attribute preference-elicitation technique that quantifies the
strength of preferences for features of products, services or health-care interventions.
Interventions, such as medical or surgical treatments in IBD, derive value from their
specific attributes, features or outcomes, including treatment efficacies, tolerability,
convenience, and potential SAE risks. In turn, each of these attributes has varying
levels, such as efficacy rates or adverse risk rates. DCEs recognize that patients have
preferences of varying strengths for different attributes and are willing to accept tradeoffs
among various levels. DCEs systematically elicit tradeoffs among constructed outcome
combinations to generate choice data that quantifies implicit decision weights indicating
relative utility for both individual treatment attributes (such as the specific risks and
benefits) as well as the treatment option as a whole. Because DCEs measure the rate
at which patients accept tradeoffs among different treatment attributes, it is also possible
to calculate a maximum acceptable risk or maximum probability of an adverse event that
participants are willing to tolerate in exchange for a given treatment benefit. DCE
increasingly has been applied in the field of healthcare for eliciting patient preferences
for a range of medical and surgical therapies across many disease states.63-69
9

Advantages of Discrete Choice Experiments
One of the most powerful advantages of DCE is that it does not require the
restrictive assumptions of conventional QALY metrics. By offering realistic benefit-risk
tradeoff scenarios within a non-expected utility framework, DCEs more accurately
quantify preference data, from which utility is derived. Houtven et al. showed how to
derive maximum acceptable risk from generalized utility theory with an example using a
DCE study in IBD.62
As patient preferences play a key role in patient satisfaction, which in turn
influences adherence and ultimately clinical outcomes, DCE-measured preference data
are more patient-centered than QALYs. Furthermore, by measuring preferences for
attributes of a medical therapy as well as the therapy overall, DCE also provides
information on the total value of an intervention or on the marginal effect of modifying a
single factor on the value. By collecting data within carefully devised experimental
designs, DCEs can introduce variability and reduce or even completely eliminate
collinearity, making possible more precise estimates of attribute contributions to therapy
utilities. This also allows for preference measurement on future interventions including
those that may not be currently available. This, in turn, can allow quantification of
patients’ risk thresholds that can help physicians, drug manufacturers and regulators
when contemplating appropriate indications for existing or new therapies, or treatment
algorithms.
The majority of DCE studies in IBD have been done in Crohn’s disease, another
type of IBD that can occur throughout the GI tract. These robust studies have examined
CD patients preferences for therapy goals; willingness to accept life-threatening SAEs in
exchange for medication efficacy; and variations in preferences by providers and
patients. In UC, DCE has been used to evaluate UC patient preferences for various
10

aspects of 5-ASA therapy.70 No prior DCE analysis, however, has examined the risk
tolerance UC patients have for escalation of medical therapy versus colectomy surgery,
a central issue for over 50% of UC patients whose disease cannot be controlled with 5ASA therapy alone.
Summary
With an increasing number of immunosuppressant medical therapies being
offered, rigorously quantifying UC patients’ risk tolerances includes their voice in an
increasingly-complex treatment paradigm. Identifying patient subgroups that are more
or less willing to accept surgery can inform physicians caring for these patients.
Determining risk and efficacy levels for which colectomy surgery is preferable to medical
therapy can inform drug efficacy trials and treatment algorithms in UC.
A conceptual model of our thesis studies is shown in Figure 1.1. We
hypothesized that UC patients perceive the benefits of medical versus surgical therapy
and have a quantifiable risk tolerance for medical therapy SAEs in preference to
colectomy surgery; however, this tolerance is modified by both clinical factors (e.g. age,
gender, disease duration, disease activity, etc.) as well as treatment factors (efficacy,
surgical outcome). To test this hypothesis, we use DCE to determine the mean
maximum acceptable risk (MAR) for SAEs associated with immunosuppressant therapy
in UC that patients are willing to accept to avoid colectomy with ostomy, IPAA or IPAA
complicated by fecal incontinence. We also evaluated how clinical characteristics and
therapy efficacy affect tolerance for medical therapy risks in preference to surgery
(Chapter 4).
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In developing the DCE survey instrument, we additionally conducted two
separate but related studies. To limit cognitive burden and numeracy concerns,
specifically confusion over conditional probabilities (the probability of an SAE conditional
on the probability of having the outcome), we sought to describe all treatment benefits as
certain and all treatment risks as known probabilities. One such attribute was that of
mortality from colorectal cancer, a risk associated with pursuance of medical therapy
(and retention, therefore, of one’s colon). While prior work had demonstrated an up to
three-times increased risk of colon cancer development in UC patients compared to the
general population,37 no evidence existed regarding the risk of colon cancer mortality in
UC. Single-center studies are often underpowered when examining outcomes such as
mortality. Meta-analysis is a statistical methodology for combining similar studies to
obtain more precise effect estimates. However, prior meta-analyses examining this
issue have come to inconsistent conclusions.71-74 Furthermore, some meta-analyses
12

have included only population-based studies, others only inception cohorts; none of the
recent meta-analyses have included referral center-based studies; and many neglected
to examine specific causes of death including colorectal cancer. Therefore, we
undertook a meta-analysis of all-cause mortality and cause-specific mortality related to
colorectal cancer, non-alcoholic liver disease, pulmonary disease and cardiovascular
disease in both UC and CD (Chapter 2). Additionally, we sought to determine how
results of population-based studies, inception cohorts, and single- or multi-center studies
vary.
We also hypothesized that one clinical factor affecting risk tolerance in UC would
be disease activity at the time of DCE survey completion. Currently, no gold-standard
for disease activity severity assessment in UC exists. However, at least 14 disease
activity indices do exist, many of which include invasive testing, laboratory tests, and/or
physician assessment that can make studies costly, difficult to implement and can deter
patient enrollment, especially with repeated measurements.75 Purely patient-driven
disease assessment indices include the Simple Clinical Colitis Activity Index (SCCAI),
which has been shown to have robust validity and reliability.76,77 While the SCCAI is
completely patient-driven, it includes some variables such as extra-intestinal
manifestations that may be ambiguous to patients and thus cause incorrect patientreporting of current disease activity. Additionally, the quantity of questions in the SCCAI
can make it cumbersome in studies with repeated measurements.
In contrast, a purely patient-driven 6-Mayo score has been infrequently utilized in
clinical research studies in UC. Two prior studies have found that the 6-Point Mayo
score correlates well with the full Mayo Clinic Score, an index most commonly used in
clinical trials but requiring both a flexible sigmoidoscopic and physician evaluation.78,79
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However, no studies had sought to correlate the 6-Point Mayo with disease severity
indices outside of the Mayo scoring system. We hypothesized that the much-simpler
two-question 6-Point Mayo would have comparable sensitivity, specificity and receiver
operating characteristic (ROC) area under the curve for patient-defined clinical remission
as the SCCAI. We therefore sought to evaluate how the 6-Point Mayo score correlated
with the SCCAI and a single Likert-scale of patient defined disease activity (Chapter 3).
We further sought to perform a validation study in a separate patient population.
The results of these studies have several important implications. For UC
patients, and the physicians and surgeons caring for them, these results provide
information regarding disease outcomes, improve understanding of UC patient risk
tolerances, and provide avenues for enhancing informed consent and shared decisionmaking for UC patients. For clinical researchers, findings from these studies provide
avenues for simpler non-invasive disease severity assessment. The results of these
studies also set new thresholds for therapies and therapeutic guidelines in UC. Finally,
our findings inform future funding proposals aimed at evaluating causes of morbidity and
mortality in IBD, measuring activity in UC, and assessing the impact of interventions
such as education on IBD patient risk tolerances.
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Abstract:
Background:
Evidence regarding all-cause and cause-specific mortality in inflammatory bowel disease
(IBD) is conflicting, and debate exists over appropriate study design to examine these
important outcomes. We conducted a comprehensive meta-analysis of all-cause and
cause-specific mortality in both Crohn’s disease (CD) and ulcerative colitis (UC), and
additionally examined various effects of study design on this outcome.
Methods:
A systematic search of PubMed and EMBASE was conducted to identify studies
examining mortality rates relative to the general population. Pooled summary
standardized mortality ratios (SMR) were calculated using random effects models.
Results:
35 original articles fulfilled the inclusion and exclusion criteria, reporting all-cause
mortality SMRs varying from 0.44 to 7.14 for UC; and 0.71-3.20 for CD. The all-cause
mortality summary SMR for inception- and population-cohort UC studies was 1.19 (95%
CI 1.06-1.35). The all-cause mortality summary SMR for inception- and populationcohort CD studies was 1.38 (95% CI 1.23-1.55). Mortality from colorectal cancer,
pulmonary disease and nonalcoholic liver disease was increased whereas mortality from
cardiovascular disease was decreased.
Conclusions:

17

Patients with UC and CD have higher rates of death from all causes, colorectal-cancer,
pulmonary disease, and nonalcoholic-liver disease.

Key words: inflammatory bowel disease, ulcerative colitis, Crohn’s disease, mortality,
meta-analysis
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Introduction:
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and
ulcerative colitis (UC), are chronic intestinal inflammatory diseases. Due to the chronic
and sometimes severe nature of this disease, there is obvious need to elucidate both allcause and cause-specific mortality, as this has important implications for patients and
more globally for issues such as public health planning.
Meta-analysis is a statistical methodology for combining similar studies to obtain
a more precise effect estimate. Prior meta-analyses examining this issue have come to
inconsistent conclusions, perhaps because of different inclusion criteria (Table 2.1).71-74
TABLE 2.1: Prior meta-analyses of IBD mortality
IBD
type
Canavan et al.,
71
2007
Dorn et al.,
72
2007
Jess et al.,
73
2007

CD

Duricova et al.,
74
2010

CD

CD
UC
UC

Included studies
(publication
year)
All study types
(1980-2004)
All study types
(1981-2006)
Inception-cohort
studies
(1982-2005)

Population-based
studies

Outcomes

SMR (95% CI)

All-cause mortality

1.52 (1.3-1.7)

Cardiovascular mortality

(0.8-1.1)
0.9 (0.8-1.0)
1.1 (0.9-1.2)
1.9 (1.0-3.8)
0.9 (0.7-1.1)
1.6 (1.3-2.0)
4.0 (2.5-6.5)

All-cause mortality
CRC mortality
Cardiovascular mortality
Respiratory disease
mortality
Non-alcoholic liver disease
mortality
All-cause mortality
All-cause cancer mortality
Pulmonary cancer mortality
Malignant melanoma
mortality
CRC mortality
Pulmonary mortality

1.39 (1.3-1.5)
1.50 (1.2-1.9)
2.72 (1.4-5.5)
10.0 (1.2-36.1)
1.3 (0.5-3.3)
1.4 (0.7-2.2)

Specifically, some meta-analyses have included only population-based studies,
others only inception cohorts; and none of the recent meta-analyses have included
referral center-based studies. Furthermore, many focused only on all-cause mortality

19

neglecting specific causes of death, critical information if one is to plan interventions to
reduce IBD-related mortality.
Therefore, we undertook a meta-analysis of all-cause mortality and causespecific mortality related to colorectal cancer, non-alcoholic liver disease, pulmonary
disease and cardiovascular disease in both UC and CD. Additionally, we sought to
determine how results of population-based studies, inception cohorts, and single- or
multi-center studies vary.
Materials and Methods:
Search strategy:
To identify published studies on this topic, a systematic search of PubMed was
performed on November 12, 2011. The search used the keywords and MESH headings
inflammatory bowel disease or ulcerative colitis or Crohn’s disease combined with
colorectal cancer or colon cancer or rectal cancer or pulmonary disease or
cardiovascular disease or hepatic disease or mortality or death or survival. A
comprehensive search of reference lists in prior meta-analyses and original studies
retrieved by this method was performed to identify additional reports. This approach
identified 15,577 papers published between 1941 and 2011. Application of the
limitations “English language journal papers” and “human studies” yielded 11,234 papers
for analysis (Figure 2.1). An search of EMBASE using the same keywords and MESH
headings was performed and no additional appropriate papers were identified.
Inclusion and exclusion criteria:
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Only full length peer-reviewed English language or English-translated papers
reporting observational study results were included to allow full evaluation of study
methods and results (such as study inclusion criteria, follow-up time, specific details of
how cause specific mortality was determined, methods of ascertainment of data and
calculation of outcome measures). All-cause and/or cause-specific mortality had to be
reported as either standardized mortality ratio (SMR), relative risk (RR), incidence rate
ratio (IRR), hazard ratio (HR) or odds ratio (OR) with or without 95% confidence
intervals. When two or more publications reported on the same patient population only
the most recent study results were included. Application of these criteria resulted in 35
original papers for
analysis (Figure 2.1).
Data Collection:
Included papers
were reviewed in detail by
two reviewers (MB and
either LK or JDL;
discrepancies were
decided by concensus
and if necessary by the
third reviewer JDL) to
determine number of
patients, gender distribution, number of UC and CD patients, calendar year of
publication, decade of the middle year of patient observation, mortality rates and/or
observed and expected numbers of deaths, 95% confidence intervals, region of IBD
21

population, type of study population and study design. In two studies, a lower 95% CI of
0.0 was reported.80,81 To allow this to be included in the summary calculations, we
approximated the lower bound to 0.025 (i.e. the midpoint between 0 and 0.049).
Studies were categorized into the following groups based on the source of the
study population: single or multi-center study if all patients observed came from the
same center or group of physicians; population-based if the IBD population was
identified within a defined geographic area; inception cohort if it was explicitly stated that
patients received their initial IBD diagnosis during their time within the cohort or if the
study explicitly stated it was a population-based inception cohort.
Statistical Analysis:
The outcome of interest was the relative mortality rate as compared to the
general population and respective 95% CIs. In the event that 95% CIs were not
calculated but observed and expected values were given, 95% CIs were calculated
using the Rothman-Greenland method. Because all but one study reported results in
terms of the SMR, we used this as our summary measure of relative risk. Pooled SMRs
with 95% CI for all-cause and cause-specific mortality were calculated using STATA’s
metan command, which uses the DerSimonian and Laird method, a random- effects
model that incorporates both between-study and within-study variation.
Statistical heterogeneity was assessed two ways. First, the I2 index and χ2 test
were used to investigate differences among studies with respect to SMRs. Additionally,
sub-group analyses were performed to assess potential sources of heterogeneity
separately due to the following available patient- and study-level factors: region of
study, study type, and decade of the middle year of patient observation. Meta22

regression analysis was also performed for heterogeneity of the all-cause SMR due to
cohort size and middle year of patient observation. Cumulative meta-analysis was
performed to examine all-cause mortality. Funnel plots of the log SMR versus its
standard error were performed to assess publication bias for analyses with five or more
studies. Begg’s rank correlation method and Egger’s regression were used to test the
correlation between effect and sample size.
Ethical Considerations: The study protocol was reviewed by the Institutional Review
Board at the University of Pennsylvania and met the criteria for exempt status.
Results:
Study Characteristics:
A total of 35 studies were included, of which 10 were inception cohorts, 13 were
population-based cohort studies, 8 were single-center studies, and 4 were multi-center
studies (Table 2.2). These studies included all studies used in prior meta-analyses
excluding one abstract used in a meta-analysis by Jess et al.73 and one study used in
the meta-analysis by Canavan et al for which data were not available.71,82
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TABLE 2.2: Studies included in meta-analysis
Study

Location

RombergCamps
81
(2010)
Solberg
83
(2009)
Hutfless
84
(2007)

Netherlands

N. America

81.6

Canavan
85
(2007)
86
Park (2007)
87
Jess (2007)

UK

288

Norway

88

Korea
Denmark

Median
Follow-up
(months)
67.2-93.6

Not reported

62.5
Not reported

Population
Size

Mortality
studied

Inception
cohort

UC: 630
CD: 476

Inception
cohort
Populationbased

UC: 519
CD: 237
UC: 5238
CD: 3241

All-cause
CV
Pulmonary
All-cause

Populationbased
Single center
Inception
cohort
Inception
cohort

CD: 394
UC: 304
UC: 1575
CD: 641
UC: 775

Hoie (2007)

EC-IBD

Delaunoit
89
(2006)
90
Jess (2006)

N. America

Not reported

N. America

168

Inception
cohort

Wolters
91
(2006)

EC-IBD

372

Inception
cohort

CD: 371

Masala
92
(2004)

Italy

177.6

Population
cohort

UC: 689
CD: 231

UK

Not reported

Populationbased
Inception
cohort

UC: 8301
CD: 5960
UC: 1160

Multi-center

CD: 544

Card (2003)

93

Winther
94
(2003)

Uno (2003)

Denmark

95

96

Japan

35

Study
Source

228

Not reported

Single center

UC: 249
CD: 49
UC: 378
CD: 314

Jess (2002)

Denmark

204

Inception
cohort

CD: 374

Viscido
80
(2001)

Italy

73.2

Multi-center

UC: 2066

Farrokhyar
97
(2001)
Katoh
98
(2000)
Ishibashi
99
(1999)
100
Saro (1999)

UK

99.6

Inception
cohort
Single center

UC: 365
CD: 196
UC: 117

Population
cohort
Population
cohort

UC: 174
CD 66
UC: 261
CD: 259

Japan

Not reported

Japan

192 (UC)
188.4 (CD)
Not reported

Spain
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All-cause
CRC
CV
Pulmonary
Hepatic
All-cause
All-cause
All-cause
All-cause
CV
Pulmonary
CRC
All-cause
CV
Pulmonary
All-cause
CV
Pulmonary
All-cause
CRC
CV
All-cause
All-cause
CRC
CV
Pulmonary
Liver
All-cause
CRC
All-cause†
CV
Pulmonary
All-cause
CRC
CV
Pulmonary
Liver
All-cause
All-cause
All-cause
CRC
All-cause

101

Palli (1998)

Italy

121.2

Davoli
102
(1997)
Persson
103
(1996)

Italy

60

Sweden

Not reported

Cottone
104
(1996)
Stewenius
105
(1995)
Probert
106
(1993)
Ekbom
107
(1992)

Southern
Europe
Sweden

93.6
Not reported

UK

Not reported

Sweden

Not reported

Probert
108
(1992)
Weterman
109
(1990)
Gyde
110
(1982)

UK

Not reported

Netherlands

Not reported

Eason
111
(1982)

New Zealand

UC: 689
CD: 231

Single center

UC: 508

Inception
cohort

UC: 1547
CD: 1251

Single center

CD: 531

Population
cohort
Population
cohort
Population
cohort

UC: 462
UC: 1014
UC: 3121
CD: 1655

All-cause††
CRC
CV
Pulmonary
All-cause
CV
All-cause
CRC
CV
Pulmonary
Liver
All-cause
CRC
All-cause
Pulmonary
All-cause

Population
cohort
Single center

CD: 610

All-cause
CRC
CV
Pulmonary
Hepatology
All-cause

CD: 671

All-cause

189.6

Multi-center

UC: 676

72

Multi-center

UC: 456
CD: 137

112

UK

Not reported

Single center

CD: 513

Ritchie
113
(1978)
114
Gilat (1976)

UK

Not reported

Single center

UC: 269

All-cause
CV
Pulmonary
All-cause
CRC
CV
All-cause
CV
Pulmonary
All-cause

UC: 504

All-cause

Iversen
115
(1968)

Denmark

Population
cohort
Population
cohort

UC: 231

All-cause

Prior (1981)

UK

Population
cohort

Israel

93.6
Not reported

*CRC: colorectal cancer; CV: cardiovascular
† Given more recent all-cause mortality rates for this population, only pulmonary and cardiovascular
mortality was used in the current study
†† Given more recent all-cause, CRC and CV mortality rates for this population, only pulmonary mortality
was used in the current study

Overall, there were 32,269 patients with CD and 18,952 patients with UC. The
year of publication ranged from 1968-2010. The median duration of follow-up (when
provided) was 83.4 months for UC and 204 months for CD.
All-cause Mortality
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The reported SMRs for all-cause mortality in patients with UC ranged from 0.44
(95% CI 0.12-1.12) to 7.14 (95% CI 1.47 to 20.70).86,100 The all-cause mortality
summary SMR for UC was 1.16 (95% CI 1.04-1.29) (Table 2.3). When combining
inception cohort and population-based studies, the all-cause mortality summary SMR for
UC was 1.19 (95% CI 1.06-1.35).
TABLE 2.3: Standardized Mortality Ratios
SummarySMR
L95%
Overall: UC
1.16
1.04
Overall: CD
1.46
1.30

U95%
1.29
1.63

I
84%
71%

2

Het p-value
0.00
0.00

# studies
25
19

Colorectal
cancer: UC
Colorectal
cancer: CD

2.82

1.68

4.74

80%

0.00

7

3.12

0.97

10.10

73%

0.00

6

Cardiovascular
disease: UC
Cardiovascular
disease: CD

0.90

0.80

1.02

39%

0.09

11

1.00

0.88

1.13

0.0%

0.73

9

Pulmonary
disease: UC
Pulmonary
disease: CD

1.41

1.12

1.77

39%

0.10

10

1.60

1.24

2.05

0.0%

0.43

8

Nonalcoholic
liver disease:
UC
Nonalcoholic
liver disease:
CD

2.26

1.14

4.49

55%

0.06

5

2.82

1.52

5.21

0.0%

0.63

3

The reported SMRs for all-cause mortality in CD patients ranged from 0.71 (95%
CI 0.51-1.01) to 3.20 (95% CI 0.38-11.50).100,108 The all-cause mortality summary SMR
for CD was 1.46 (95% CI 1.30-1.63) (Table 2.3). When combining inception cohort and
population-based studies, the all-cause mortality summary SMR for CD was 1.38 (95%
CI 1.23-1.55).
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There was significant heterogeneity in the all-cause summary SMR across levels
of patient- and study-level factors for both UC and CD (Table 2.4). Twelve studies
reported on gender-specific overall mortality for UC and CD, with a possible trend
towards higher relative mortality in females (Table 2.4). However, there remained
significant among-study heterogeneity when examining men and women separately.
TABLE 2.4: All-Cause Standardized Mortality Ratios*†
Pooled
ES

L95%

U95%

I

2

Het pvalue

#
studies

1.10
1.29

0.94
1.01

1.28
1.64

56%
76%

0.01
0.00

12
12

1.32
1.63

1.11
1.38

1.57
1.93

55%
57%

0.01
0.01

12
12

0.92
1.21
1.23
1.01
1.14
1.09

0.74
0.96
1.10
0.69
0.65
0.86

1.14
1.54
1.40
1.49
2.01
1.38

55%
86%
79%
80%
76%
…..

0.14
0.00
0.00
0.00
0.00
…..

2
5
8
4
5
1

1.36
1.30
1.54
1.62
1.29
1.85

1.19
0.99
1.29
1.23
0.72
1.30

1.54
1.72
1.84
2.14
2.33
2.55

0%
90%
73%
0%
0%
…..

0.35
0.00
0.01
0.62
0.89
…..

2
5
5
3
3
1

1.08
1.32
1.03
1.16
1.16

0.97
1.07
0.77
0.73
1.04

1.21
1.63
1.38
1.83
1.29

67%
90%
22%
90%
84%

0.00
0.00
0.28
0.00
0.00

8
10
4
3
25

1.34
1.39
2.06
1.25
1.46

1.15
1.18
1.78
0.67
1.30

1.56
1.64
2.38
2.32
1.63

49%
77%
0%
0%
71%

0.08
0.00
0.68
0.67
0.00

6
8
3
2
19

0.44
1.04
1.05

0.12
0.83
0.99

1.12
1.31
1.12

….
90%
0%

….
0.00
0.77

1
6
7

UC
Men
Women
CD
Men
Women
UC
all-cause
North America
United Kingdom
North Europe
South Europe
Other countries
EC-IBD
CD
all-cause
North America
United Kingdom
North Europe
South Europe
Other countries
EC-IBD
UC
all-cause
Inception
Population
Single-center
Multi-center
All-studies
CD
all-cause
Inception
Population
Single-center
Multi-center
All-studies
UC
all-cause
Decade 2000s
Decade 1990s
Decade 1980s
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Decade 1970s
Decade 1960s
Decade 1950s

1.21
2.26
1.70

1.01
1.79
1.48

1.45
2.86
2.06

74%
0%
…..

0.00
0.42
…..

8
2
1

CD
all-cause
Decade 2000s
…..
…..
…..
…..
…..
0
Decade 1990s
1.54
1.32
1.79
54%
0.07
5
Decade 1980s
1.14
0.84
1.55
62%
0.02
6
Decade 1970s
1.42
1.27
1.59
35%
0.18
6
Decade 1960s
2.09
1.79
2.43
0%
0.49
2
Decade 1950s
…..
……
…..
…..
….
0
*Numbers of studies reporting from respective regions of the world: North America (3); United Kingdom (8);
Northern Europe (9); Southern Europe (6); Other Regions (6); European Collaborative Study Group of
Inflammatory Bowel Disease (EC-IBD) (2)
† Decade refers to decade of the middle year of patient observation in study

Meta-regression was carried out to explore evidence that between-study
heterogeneity could be due to cohort size or decade of the middle year of patient
observation, two variables universally available in all studies. For all-cause mortality in
UC and CD, the SMR was not associated with cohort size (p=0.71 and p=0.43
respectively) or decade of middle year of patient observation (p=0.06 and p=0.28
respectively).
Subgroup analyses were performed stratified by geographic region (Table 2.4).
Despite the reduced number of studies, there remained significant heterogeneity in most
of the regional subgroup analyses for all-cause mortality.
Study Type
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Figure 2.2 shows the similarity of the population-based studies and inception
cohort studies examining all-cause mortality in UC. Inception cohort, single-center and

multi-center studies all showed non-significant SMRs of similar elevated magnitude
[summary SMRs 1.08 (95% CI 0.97-1.21), 1.03 (95% CI 0.77-1.38) and 1.16 (95% CI
0.73-1.83) respectively)]. A significantly elevated SMR was observed for populationbased studies (summary SMR 1.32, 95% CI 1.07-1.63) (Table 2.4). However, this
estimate fell within the range of mortality estimates for other study types and there
remained significant heterogeneity within the subgroup of population-based studies
(Table 2.4 and Figure 2.2). Therefore, heterogeneity of the all-cause mortality summary
estimate could not be accounted for by study type for UC.
For all-cause mortality in CD, higher SMRs were reported in single-center studies
than for inception or population based studies [(summary SMRs 2.06 (95% CI 1.782.38), 1.34 (95% CI 1.15-1.56) and 1.39 (95% CI 1.18-1.64) respectively)]. Multi-center
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studies had a non-significant all-cause summary SMR of 1.25 (95% CI 0.67-2.32).
These data suggest that heterogeneity among CD studies was partly explained by
inclusion of single-center studies. However, significant heterogeneity remained in the
inception and population-based studies (p=0.08 and p ≤ 0.01 respectively).
Cumulative meta-analysis was carried out to examine how the summary mortality
estimate for all-cause mortality in UC and CD changed with successive published
inception and inception plus population-based cohort studies (see Figure 2.3). For UC,
the dates of inception-cohort studies ranged from 1996 to 2010; and ranged from 1968
to 2009 for population-based cohort studies. The summary mortality estimate for both
study cohort types was attenuated over time (see Figure 2.3). In the inception cohort
only studies, the summary mortality estimate became non-significant over time (SMR
1.08, 95% CI 0.97-1.21). The addition of population cohort studies yielded a very similar
summary estimate that remained slightly elevated over time (SMR 1.17, 95% CI 1.041.32). Additional cumulative meta-analysis was performed removing the studies from
1968 and 1976; the resulting dates of studies ranged from 1992-2010. The summary allcause mortality estimates remained very similar to that of inception-only studies (SMR
1.10, 95% CI 0.99-1.23).
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For CD, inception cohort-only studies ranged from 1996-2010; with the addition
of population cohort studies, the date of the studies ranged from 1992-2010 (see Figure
2.3). The summary mortality estimate for all-cause mortality remained fairly constant
over time for both inception cohort studies alone and inception plus population cohort
studies (SMR 1.34, 95% CI 1.15-1.56; and SMR 1.37, 95% CI 1.22-1.53 respectively).
Analysis of Cause Specific Mortality
Significantly elevated SMRs for colorectal cancer, pulmonary disease, and
nonalcoholic liver disease were observed in UC; and significantly elevated SMRs for
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pulmonary disease and nonalcoholic liver disease were observed in CD (Table 3).
However, for patients with UC and CD, the SMR for cardiovascular disease related
mortality rates was not significant; and for patients with CD, the SMR for colorectal
cancer mortality was not significant, although there appeared to be a trend towards
significance. Significant heterogeneity was observed for CRC-related mortality in UC
and CD. There was borderline heterogeneity for hepatic- and cardiovascular-related
mortality in UC (Table 2.3). Because of the small number of studies, all study types
were included in cause specific mortality analysis (Table 2.3); and only qualitative
comparisons were made across geographic region or study type for cause specific
mortality (Table 2.5). Differences in definitions of cause specific mortality are
summarized in Table 2.6.
Table 2.5. Cause-specific Standardized Mortality Estimates*†
Summary
SMR

L95%

U95%

I

2

Heterogeneity
p-value

#
studies

1.80

1.04

3.12

0.0%

0.36

2

0.73

0.26

2.04

0.0%

0.59

2

0.93

0.69

1.24

41%

0.13

6

0.93

0.69

1.25

21%

0.28

6

1.13

0.59

2.17

46%

0.12

5

1.55

1.07

2.26

0.0%

0.87

4

1.67

0.04

9.28

….

….

1

3.50

1.64

7.45

….

….

1

0.87

0.61

1.25

0.0%

0.82

5

1.22

0.70

2.11

53%

0.08

5

1.54

0.91

2.63

0.0%

0.62

5

UC
Colorectal
cancer: men
Colorectal
cancer: women
Cardiovascular
disease: men
Cardiovascular
disease: women
Pulmonary
disease: men
Pulmonary
disease: women
Nonalcoholic liver
disease: men
Nonalcoholic liver
disease: women

NS

CD
Colorectal
cancer: men
Colorectal
cancer: women
Cardiovascular
disease: men
Cardiovascular
disease: women
Pulmonary
disease: men

NS
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Pulmonary
disease: women
Nonalcoholic liver
disease: men
Nonalcoholic liver
disease: women

2.054

1.408

2.997

0.0%

0.56

5

3.60

1.00

9.20

….

….

1

North America
United Kingdom
North Europe

1.60
NS
2.60

0.90

2.80

….

….

1

1.27

5.29

0.01

3

South Europe

2.31

0.87

6.09

0.14

2

Other countries
EC-IBD††

9.93
NS

4.67

17.3

79.4
%
54.7
%
….

….

1

North America

0.76

0.52

1.13

0.09

2

United Kingdom
North Europe

0.70
1.01

0.45
0.90

1.10
1.15

…..
0.31

1
4

South Europe
Other countries
EC-IBD††

0.72
NS
1.07

0.56

0.93

65.9
%
….
16.9
%
0.0%

0.79

3

0.71

1.54

….

….

1

1.15
0.80
1.64
0.18
NS
2.01

0.84
0.36
1.34
0.00

1.59
1.60
2.00
1.10

0.0%
….
0.0%
….

0.56
….
0.57
….

2
1
5
1

1.00

3.60

….

….

1

North America
United Kingdom
North Europe

1.20
NS
3.50

0.40

2.60

….

….

1

2.05

5.98

0.28

3

South Europe
Other countries
EC-IBD††

0.50
NS
NS

0.03

3.00

22.4
%
….

…

1

North America
United Kingdom
North Europe

1.90
NS
1.08

0.90

3.70

….

…

1

0.24

4.81

0.22

2

South Europe
Other countries

3.86
64.4

0.86
7.72

17.20
232.5
0

34.4
%
0.0%
….

0.45
…

2
1

EC-IBD††

NS

NS

UC
Colorectal
cancer

UC
Cardiovascular
disease

UC
Pulmonary
disease
North America
United Kingdom
North Europe
South Europe
Other countries
EC-IBD††
UC
Nonalcoholic
liver disease

CD
Colorectal
cancer
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CD
Cardiovascular
disease
North America
United Kingdom
North Europe
South Europe
Other countries
EC-IBD††

0.96
0.80
1.03
0.65
NS
1.49

0.77
0.50
0.88
0.24

1.19
1.38
1.21
1.41

0.0%
….
0.0%
….

0.41
….
0.78
….

2
1
4
1

0.74

2.66

….

….

1

1.89
0.90
1.28
NS
NS
2.66

1.35
0.42
0.81

2.64
2.06
2.03

0.0%
….
0.0%

0.94
….
0.50

2
1
4

0.72

6.80

….

….

1

2.60
NS
3.10
NS
NS
NS

1.00

5.30

….

….

1

1.24

7.73

0.0%

0.36

2

Inception
Population

2.85
2.60

1.59
1.21

4.69
5.61

….
86.4
%

….
0.00

1
5

Single-center
Multi-center

NS
3.46

1.58

6.57

….

….

1

Inception

1.00

0.82

1.23

0.10

5

Population

0.90

0.79

1.04

0.24

4

Single-center
Multi-center

0.65
0.76

0.26
0.56

1.34
1.02

49.4
%
29.6
%
….
0.0%

….
0.66

1
2

Inception

1.60

1.22

2.10

0.34

5

Population
Single-center
Multi-center

1.49
NS
0.49

1.24

1.80

11.4
%
0.0%

0.41

4

0.13

1.94

51.7
%

0.15

2

4.80
1.91

2.07
0.79

9.45
4.60

….
57.4

….
0.10

1
3

CD
Pulmonary
disease
North America
United Kingdom
North Europe
South Europe
Other countries
EC-IBD††
CD
Nonalcoholic
liver disease
North America
United Kingdom
North Europe
South Europe
Other countries
EC-IBD††
UC
Colorectal
cancer

UC
Cardiovascular
disease

UC
Pulmonary
disease

UC
Nonalcoholic
liver disease
Inception
Population
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%
Single-center
Multi-center

NS
0.50

0.03

3.00

….

….

1

0.30
1.82
5.40
64.40

0.01
1.03
0.60
7.72

1.67
3.22
19.00
232.5
0

….
0.0%
….
….

….
0.97
….
….

1
3
1
1

0.97
1.04
0.80
NS

0.79
0.88
0.50

1.19
1.22
1.38

0.0%
0.0%
….

0.60
0.49
….

5
3
1

Inception
Population

1.67
1.33

1.11
0.52

2.49
3.39

0.75
0.09

5
2

Single-center
Multi-center

0.90
NS

0.42

2.06

0.0%
65.0
%
….

….

1

0.91
2.99
NS
NS

0.02
1.59

5.10
5.62

….
0.0%

….
0.62

1
2

0.0%
87.5
%
46.7
%

0.71
0.00

2
3

0.17

2

34.5
%
18.2
%
74.1
%

0.21

4

0.29

3

0.02

3

….

….

1

CD
Colorectal
cancer
Inception
Population
Single-center
Multi-center
CD
Cardiovascular
disease
Inception
Population
Single-center
Multi-center
CD
Pulmonary
disease

CD
Nonalcoholic
liver disease
Inception
Population
Single-center
Multi-center
UC
Colorectal
cancer
Decade 2000s
Decade 1990s
Decade 1980s

NS
1.53
3.30

0.92
0.94

2.53
11.67

Decade 1970s

3.76

2.50

5.66

Decade 1960s
Decade 1950s

NS
NS
UC
Cardiovascular
disease

Decade 2000s
Decade 1990s

NS
0.92

0.74

1.13

Decade 1980s

0.94

0.73

1.20

Decade 1970s

0.89

0.69

1.16

Decade 1960s
Decade 1950s

NS
0.70

0.45

1.10

UC
Pulmonary
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disease
Decade 2000s
Decade 1990s

NS
1.33

0.84

2.11

Decade 1980s

0.67

0.08

5.69

Decade 1970s
Decade 1960s
Decade 1950s

1.60
NS
0.80

1.25

0.21

3

0.02

2

2.03

36.1
%
80.5
%
0.0%

0.41

4

0.36

1.60

….

….

1

0.40
0.15
2.46

2.60
3.20
5.93

….
0.0%
0.0%

….
0.72
0.47

1
2
2

0.0%
75.1
%
34.4
%

0.85
0.05

2
2

0.22

2

UC
Nonalcoholic
liver disease
Decade 2000s
Decade 1990s
Decade 1980s
Decade 1970s
Decade 1960s
Decade 1950s

NS
1.20
0.70
3.82
NS
NS
CD
Colorectal
cancer

Decade 2000s
Decade 1990s
Decade 1980s

NS
1.87
18.73

0.94
1.65

Decade 1970s

1.08

0.24

3.72
212.5
9
4.81

Decade 1960s
Decade 1950s

NS
NS

NS
1.03
0.90
1.01
0.80
NS

0.84
0.50
0.85
0.50

1.28
1.50
1.19
1.38

0.0%
…..
0.0%

0.47
…..
0.42
…..

4
1
3
1

NS
1.91
1.38
1.45
0.90
NS

1.35
0.59
0.88
0.42

2.69
2.71
2.41
2.06

0.0%
…..
8.1%

0.50
….
0.34
…..

3
1
3
1

CD
Cardiovascular
disease
Decade 2000s
Decade 1990s
Decade 1980s
Decade 1970s
Decade 1960s
Decade 1950s
CD
Pulmonary
disease
Decade 2000s
Decade 1990s
Decade 1980s
Decade 1970s
Decade 1960s
Decade 1950s
CD
Nonalcoholic
liver disease
Decade 2000s
NS
Decade 1990s
2.60
1.00
5.30
….
….
Decade 1980s
NS
Decade 1970s
3.10
1.24
7.73
0.0%
0.36
Decade 1960s
NS
Decade 1950s
NS
*NS—no studies; EC-IBD--European Collaborative Study Group of Inflammatory Bowel Disease
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1
2

†Decade refers to decade of the middle year of patient observation in study

Table 2.6: Table of included diagnoses (ICD codes) for cause-specific mortality
Study

Colorectal
cancer

Romberg-Camps
81
(2010)
83
Solberg (2009)
84
Hutfless (2007)
85

Canavan (2007)
86
Park (2007)
87
Jess (2007)
88
Hoie (2007)
89
Delaunoit (2006)
90
Jess (2006)
91
Wolters (2006)
92
Masala (2004)
93
Card (2003)
94
Winther (2003)
95

Uno (2003)
96
Jess (2002)
80

Viscido (2001)
Farrokhyar
97
(2001)
98
Katoh (2000)
99
Ishibashi (1999)
100
Saro (1999)
101
Palli (1998)
102
Davoli (1997)
103
Persson (1996)
104

Cottone (1996)
Stewenius
105
(1995)
106
Probert (1993)
107
Ekbom (1992)

108

NA

Cardiovascular
disease
ICD10: 099-118

Pulmonary
disease
ICD10: 122–134

Nonalcoholic
liver disease
NA

NA
ICD9: 153–154
ICD10: C18–C20

NA
ICD9: 390-459
ICD10: I00 –I99

NA
ICD9: 466 –519
ICD10: J02–J98

NA
NA
NA
NA
NR
NA
NA
ICD9: 153–154
NA
ICD10: C18C20.9
NR
NA

NA
NA
NA
ICD10: 099-118
NA
ICD9: 390–459
NR
ICD9: 390–459
NA
ICD10: I00-I52.9

NA
NA
NA
ICD10: 122-134
NA
ICD9: 460–519
NR
NA
NA
ICD10: J00-99
NA
ICD10: J00-99

ICD9: 153-154
NA

NA
ICD10: I00-25,
I27, I30-52
ICD9: 390-459
NA

NA
ICD9: 571
ICD10: K70–
K76
NA
NA
NA
NA
NA
NA
NA
NA
NA
ICD10: K7177.9
NA
NA

ICD9: 460~519
NA

ICD9: I 55
NA

NA
ICD9: 153-154
NA
ICD9: 153-154
NA
ICD9: 153–154

NA
NA
NA
ICD9: 390–459
ICD9: 390-459
ICD9: 390–458

NA
NA
NA
ICD9: 460–519
NA
ICD9: 460–519

NR
NA

NA
NA

NA
NR

NA
NA
NA
NA
NA
ICD9: (570–573
excluding 571.0
NA
NA

NA
ICD7: 153–154
ICD8: 153–154

NA
ICD7: 400-468
ICD8: 390-458

NA
ICD7: 470-527
ICD8: 480-519

NA
NA

NR
NR

NA
ICD7: 580-583
(excluding
5811)
ICD8: 570-573
(excluding
5170)
NA
NA

ICD7: 400-468
NR
ICD7: 400-468
NA
NA
NA

ICD7: 470-527
NA
ICD7: 470-527
NA
NA
NA

NA
NA
NA
NA
NA
NA

Probert (1992)
NA
Weterman
NA
109
(1990)
110
Gyde (1982)
NA
111
Eason (1982)
NR
112
Prior (1981)
NA
113
Ritchie (1978)
NA
114
Gilat (1976)
NA
115
Iversen (1968)
NA
NA: Not Applicable; NR: Not Reported
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Publication Bias
There was no evidence of publication bias for all-cause mortality or causespecific mortality for UC or CD (p>0.09 for all tests).
Discussion:
The present meta-analysis shows a small increase in all-cause mortality for both
UC and CD. Cause-specific analysis reveals significantly increased mortality from CRC,
pulmonary disease and nonalcoholic liver disease for UC; and from pulmonary and
nonalcoholic liver disease for CD. Cardiovascular-related mortality was not elevated for
either UC or CD, which is congruent with prior meta-analysis72.
We examined geographic region, time period and study design as potential sources of
heterogeneity, but none entirely explained the observed heterogeneity among all-cause
mortality.
This is the first meta-analysis to conclude that patients with UC have an
increased mortality rate relative to the general population. We observed this in the
overall analysis of all-cause mortality, in population-based studies, in population plus
inception cohort studies, but not in inception cohort studies alone. A prior meta-analysis
of inception cohort studies by Jess et al also did not observe a significantly increased
mortality rate relative to the general population.73 Of note, our meta-analysis included
four new inception cohort studies not included by Jess et al.81,83,87,97 However, we also
categorized five studies in the Jess meta-analysis as population-based but not inception
cohorts because it was not specifically stated that patients received their initial IBD
diagnosis during their time within the cohort or the study did not explicating state it was
an inception-cohort study.92,94,105-107,111 Additionally, we excluded abstracts from our
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analysis while there was one abstract included in the Jess meta-analysis. These
conservative efforts in study inclusion and classification may have contributed to the
slightly different results. However, importantly, the summary SMRs for inception and
population-based studies were similar in magnitude (UC inception 1.08, population 1.32;
CD inception 1.34, population-based 1.39) and as expected combining inception cohorts
and population-based studies yielded similar results (UC 1.17 (95% CI 1.04-1.32); CD
1.37 (95% CI 1.22-1.53)).
Inception cohorts by definition include all follow-up time in the early stages of
disease but may not be able to follow patients for a sufficiently long time period in the
later years of disease to fully assess long-term risk of mortality, in particular cancerrelated mortality and mortality related to long-term complications of IBD. In contrast,
non-inception population-based cohorts include some patients in the early stages of
disease and others with late stage disease. Thus inception cohorts are better suited to
capture early mortality as their observation time occurs at the onset of disease; while
population-based studies are better suited to capture late mortality given their
observation time occurs at any stage of disease. It has been suggested that all-cause
mortality from UC peaks within the first year of diagnosis.1,116-118 If this were the case,
inception cohort studies would be expected to observe higher all-cause mortality rates
than population-based studies. Unfortunately, in our study, we were unable to assess
whether the relative risk of mortality varied by years after IBD diagnosis.
We used cumulative meta-analysis and meta-regression to examine trends in
relative mortality rates over time. We hypothesized that, over time, the overall mortality
rates for IBD patients would move towards 1.0. For UC, this was evident examining the
earliest studies with continued improvement over the range of the cumulative meta39

analysis, and from our analysis excluding the two earliest studies where the summary
SMR is not significantly elevated. This may be due to improved surgical options for UC
over time. However, for CD, overall mortality has not shown a significant change over
time. Given that there were no studies meeting our inclusion criteria documenting
mortality rates in the 2000’s, it remains possible that there has been a decrease in
mortality due to improved medical therapy in recent years. Given the shift in treatment
patterns including more frequent use of thiopurines, methotrexate and anti-TNFα
therapies, this is an important question for future research.46,119
This current study suggests multiple potential sources of elevated mortality
including CRC, and pulmonary- and hepatic-disease, some of which may be preventable
deaths (Table 3). Prior meta-analyses and reviews of these studies have found elevated
pulmonary-related mortality in IBD, with observed causes including COPD (CD) and
pneumonia (UC).73,74,120 Our current meta-analysis evaluated a greater number of
studies and found similarly elevated pulmonary-related relative mortality for both UC and
CD. It is plausible that similar causes drove our all cause mortality findings as well,
raising potential avenues for intervention including increase use of smoking cessation
counseling and pneumonia and influenza vaccines.
Similarly to Jess et al, we observed an elevated relative risk of death for nonalcoholic liver disease mortality in UC.73 It has long been recognized that patients with
UC are at an increased risk of primary sclerosing cholangitis (PSC) and its
complications.121 We also found that CD patients had a slightly higher relative risk of
dying from liver disease. This finding raises the question of whether PSC is more
aggressive in CD, under recognized in CD,122 or if another form of liver disease is driving
this increased mortality, such as fatty liver disease. These findings suggest potential
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utility of monitoring in IBD patients for liver disease, although this has never been proven
in clinical trials.
Death from CRC-related mortality has long been described in IBD, although the
two most recent meta-analyses showed a non-significant or marginally significantly
increased CRC-related mortality in CD and UC, respectively.73,74 Our current metaanalysis found an elevated risk of relative mortality for CRC in UC and a trend towards
an elevated risk of CD. Our inclusion of single and multi-center studies could have
contributed to this. In our stratified analysis for UC, all study types yielded elevated
relative risks of mortality for CRC, although multi-center studies did contribute the
highest risk (see Table 5). In contrast, for CD, there was an elevated relative risk of
mortality for the population-based studies and the two referral-based studies, but not for
the inception-based study (see Table 5). It is possible, as discussed above, that
inception cohorts were not able to follow patients for a sufficiently long time period to
capture long-term mortality such as colorectal cancer.
It is plausible that the relative risk of CRC mortality is decreasing over time, as
access to care and screening for CRC has increased.123 Although we were
underpowered to make strong correlations, there appeared to be a trend towards
decreased relative mortality over decade time in UC, although not in CD (see Table 5).
This could reflect greater awareness of the need for CRC surveillance in UC, although
recent evidence argues against this.124 Alternatively, there could be more frequent use
of chemopreventative agents such as mesalamine in UC than in CD, albeit these
chemopreventative effects have not been definitively proven.125 Finally, reduction in
CRC-related relative mortality among IBD patients would need to exceed that observed
in the general population for this to be evident as a relative risk reduction. Increased
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CRC screening in the general population could obscure improvements in CRC-related
mortality among patients with IBD when using relative risk estimates as the summary
measure.
There are several limitations in this study. In some cases, cause of death was
ascertained from death certificates and therefore subject to potential misclassification
bias. As described above, there is the potential for misclassification of inception versus
population cohort studies. SMRs are only age- and sex-adjusted; therefore other
characteristics of the study populations may have contributed to heterogeneity. For
example, we were unable to assess whether current or former smoking contributed to
excess mortality. Disease severity was not assessed in the included studies and
therefore we were unable to assess heterogeneity in overall mortality by disease
severity. Finally, we could not determine whether the attributable risk of death due to
IBD differs by age. These all remain important questions.
In summary, this is the largest and most comprehensive meta-analysis
evaluating all-cause and cause-specific mortality in IBD to date. This is the first metaanalysis to observe an elevated overall relative mortality for patients with UC. We found
little evidence of significant differences in all-cause relative mortality summary estimates
for population- versus inception-based studies for either UC or CD. We also confirmed
the previously reported increased all-cause relative mortality for patients with CD.
Additionally, we have found statistically increased colorectal-, pulmonary- and nonalcoholic liver disease-related relative mortality for UC; and a statistically increased
pulmonary- and non-alcoholic liver disease-related relative mortality for CD.
Cardiovascular-related relative mortality was not elevated for either UC or CD. Further
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work evaluating specific etiologies of these cause-specific mortalities is likely to be
illuminating.
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Abstract:
Background & Aims:
There is a need for a simple, non-invasive patient-driven disease assessment instrument
to facilitate clinical research in ulcerative colitis (UC). Therefore, we sought to determine
the reliability of a simple two-item index that does not require physician contact,
knowledge of extraintestinal manifestations, endoscopy, stool or blood tests to measure
disease activity.
Methods:
A cross-sectional study was conducted to assess the correlation of the 6-Point Mayo
score with the Simple Clinical Colitis Activity Index (SCCAI) and a single Likert-scale of
patient-defined disease activity. Spearman’s correlation, sensitivity, specificity and area
under the receiver-operator curves (ROC) were calculated. Subgroup analysis was
conducted in patients with more severe UC, defined as current or prior exposure to
immunosuppressant therapy. A separate validation study was conducted in which
additional analysis was performed evaluating performance characteristics in left-sided
and pancolitis UC.
Results:
The 6-Point Mayo score was strongly correlated with the SCCAI (rho = 0.71, p<0.0001)
and with patient-driven reported disease activity (rho = 0.65, p<0.0001). The SCCAI
was similarly correlated with patient-driven reported disease activity (rho = 0.66,
p<0.0001). Using a cut point of 1.5, the 6-Point Mayo score had a sensitivity of 83% and
a specificity of 72% for patient-defined remission; and a sensitivity of 89% and a
specificity of 67% for SCCAI-defined remission (score <2.5). The 6-Point Mayo score
and SCCAI had similar accuracy of predicting patient-defined remission, with an area
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under the ROC curve of 0.84 and 0.87, respectively. Addition of the SCCAI urgency and
general well-being questions to the 6-Point Mayo resulted in an area under the ROC
curve of 0.90. Similar findings were seen in the populations of patients with current or
prior exposure to immunosuppressant therapy; however, addition of the SSCAI urgency
and general well-being in this population did not significantly improve the discriminative
ability of the index. In the external validation study, strong correlations were again seen
between the 6-Point Mayo score and SCCAI (rho = 0.73, p <0.0001) and patient-driven
reported disease activity (rho = 0.63; p < 0.0001); and between the SCCAI and patientdriven reported disease activity (rho = 0.73; p <0.0001). These significant correlations
remained when examining patients with left-sided colitis and pan-colitis UC. In the full
validation cohort, the 6-Point Mayo score had a sensitivity of 90% and a specificity of
65% for patient-defined remission; and a sensitivity of 95% and specificity of 79% for
SCCAI-defined remission. Both the 6-Point Mayo score and SCCAI had similar
accuracy of predicting patient-defined remission, with an area under the ROC curve of
0.80 and 0.87, respectively. Addition of both the SCCAI general well-being and urgency
components significantly improved the 6-Point Mayo ability to predict patient-defined
remission. None of the clinical activity indices examined (the 6-Point Mayo, the SCCAI
or a single Likert-scale of patient-defined disease activity) had good correlations with the
UC Endoscopic Index of Severity (UCEIS).
Conclusions:
The 6-Point Mayo score correlates strongly with the SCCAI and with patient-reported
disease activity and represents a simple option for assessing disease activity in UC in
clinical trials and observation studies without requiring direct physician contact. The
addition of information regarding urgency and general well-being improved the test
operating characteristics.
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Background:
Ulcerative colitis (UC) is a chronic relapsing inflammatory disease of the colon.
Assessment of disease severity is useful in the conduct of clinical research related to
UC. Often disease activity needs to be assessed not only at study initiation but at
repeated time points throughout the study. Currently, no gold-standard for disease
severity assessment in UC exists. However, at least 14 disease activity indices have
been developed, many of which include invasive testing, laboratory tests, and/or
physician assessment that can make studies costly, difficult to implement and can deter
patient enrollment, especially with repeated measurements.75 Therefore, there is a need
for a simple, non-invasive patient-driven disease assessment instrument.
One disease severity index that does not require physician assessment, invasive
testing or laboratory tests is the Simple Clinical Colitis Activity Index or SCCAI (Table
3.1).126 This index includes six variables that were found to best predict the original
Powell-Tuck classification of UC remission: bowel frequency during the day and night,
urgency of defecation, blood in the stool, general well-being and extra-colonic
manifestations of UC. The SCCAI has been shown to have robust discriminative and
construct validity as well as test-retest reliability and responsiveness to change; and a
score of < 2.5 points has been shown to correlate with Patient-Defined Remission.76,77 It
has also been shown to correlate well with invasive indices of UC disease activity.127
While the SCCAI is completely patient-driven, it includes some variables such as extraintestinal manifestations that may be ambiguous to patients and thus cause incorrect
patient-reporting of current disease activity. Additionally, the quantity of questions in the
SCCAI can make it cumbersome in studies with repeated measurements.
The Mayo Score is the index most commonly used in clinical trials and consists
of only four items: stool frequency, rectal-bleeding, flexible sigmoidoscopic examination
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and a physician global assessment (Table 3.1).128 A non-invasive 9-Point Mayo or
Partial Mayo incorporates stool frequency, rectal bleeding and the physician’s global
assessment. The Partial Mayo has been found to correlate closely with the full Mayo
score, and to independently have strong discriminative and construct validity and
responsiveness to change in disease activity.77,78 However, this scoring system still
requires face-to-face evaluation with a physician. Therefore, a purely patient-driven 6Point Mayo has also been infrequently utilized. Two prior studies have found that the 6Point Mayo correlates very well with the Partial and Full Mayo scores, and a cut-off of
1.5 has been shown to correlate with patient-defined remission.78,79 However, no study
has sought to correlate the 6-Point Mayo score with disease severity indices outside of
the Mayo scoring system. Therefore, the aim of our study was to assess the correlation
of the 6-Point Mayo score with the SCCAI and a single Likert-scale of patient defined
disease activity (Table 3.1). We also sought to evaluate correlations between the 6Point Mayo, the SCCAI and patient-defined disease activity in patients with more severe
disease, as defined as current or prior exposure to immunosuppressant therapy. To
further confirm these findings, we conducted a validation study in a separate population
of UC patients with defined disease distribution.
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Materials and Methods
Data for the initial study were acquired from a recently completed mailed
questionnaire-based conjoint analysis study conducted at the University of Pennsylvania
and Dartmouth-Hitchcock Medical Center. The purpose of this conjoint analysis study
was to assess patient preferences for surgical versus medical therapy for a UC disease
flare. The study included patients ≥ 18 years old with an International Statistical
Classification of Diseases (ICD)-9 code for UC (556.0-556.6 and 556.8-556.9), no
concomitant ICD-9 code for Crohn’s disease (555.0-555.2, 555.9) and an outpatient
gastroenterology clinic visit within the prior 24 months. The survey included two
separate questions asking participants if they had UC. To be included in this substudy,
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participants had to answer both questions in the affirmative and have no missing data for
any of the disease severity questions that are described below.
The survey instrument included all aspects of the SCCAI and the 6-Point Mayo
score. Illustrations and descriptions aimed at a 6-grade reading level were used to
illustrate the extra-intestinal manifestation questions in the SCCAI to limit patient
confusion or lack of understanding of the medical terminology in the index. Furthermore,
we included a single patient-driven disease activity question that read, “Please check
what you would describe as your ulcerative colitis activity over the past 3 days.” There
were six possible responses to this question (Table 3.1).
The validation study utilized the same SCCAI and 6-Point Mayo indices
questions (including the illustrations and descriptions) as well as the single patient-driven
disease activity question utilized in the initial study. This study was administered to
consecutively enrolled clinic patients in separate prospective cohort study at the
University of Pennsylvania (IBD Immunology Initiative or I3 study). All patients were ≥
18 years old with an ICD-9 code for UC (556.0-556.6 and 556.8-556.9) confirmed by a
gastroenterologist and verified by review of the patient’s electronic medical record.
Patients also had to be capable of providing informed consent. Review of the patient’s
electronic medical record also served to confirm disease extent (left-sided colitis versus
extensive colitis).
Descriptive statistics were used to describe patients included in the study.
Continuous variables are reported as medians; and categorical variables as proportions.
Correlations were measured using Spearman correlation coefficients (rho). To assess
sensitivity and specificity for the SCCAI and the 6-point Mayo we used the patient-driven
disease activity question as the gold standard. Clinical remission was defined as a selfassessment of perfect or very good (minimal disease activity). Receiver operating
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characteristic (ROC) curves were generated and area under the ROC curves (AUC) for
different disease indices were computed. Logistic regression modeling and chi-square
tests were used to compare AUC from different ROC curves. SAS v.9.1 was used for
data management and analysis. The study design was approved by the Institution
Review Boards at both the University of Pennsylvania and Dartmouth Hitchcock Medical
Center
Results
Initial Survey
The survey for the
initial study was mailed to
775 UC patients and
responses were received
from 442 patients (57%
response rate). We had
limited information on nonresponders, but men were
less likely to respond (data
not shown). After applying
the exclusion criteria, 282
participants were included in
the final analysis (Figure
3.1).
Baseline
demographics of the initial
survey population are shown in Table 3.2. The majority of respondents were female and
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Caucasian with a mean age of 47 years. Most had UC for more than one year with a
mean duration of disease of 13 years. 29% stated they were having a current flare of
their UC. The majority of respondents were on or had been on some form of 5-ASA
therapy for their UC. The majority also had prior exposure to corticosteroids, although
only 11% were currently taking corticosteroids. Approximately one-third of respondents
were currently on some form of immunosuppressant therapy (including thiopurine,
cyclosporine, methotrexate or anti-TNF therapies) and an additional 20% had prior
exposure to immunosuppressant therapy for their UC (Table 3.2).
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SCCAI, 6-Point Mayo and Patient Assessment of Disease Activity
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The results of the disease severity assessments for the full survey population are
shown in Table 3.3. 63% of the surveyed population were in a remission defined by the
6-point Mayo or patient-driven activity question. Notably, however, only 53% were in a
remission defined by the SCCAI. Among the 152 patients who had prior or current
exposure to immunosuppressant therapy, there were slightly higher SCCAI mean and
median scores; and overall, 4% fewer patients were in remission across each of the
indices. Again, a fewer percentage of patients with prior or current exposure to
immunosuppressant therapy were considered to be in a remission by the SCCAI (49%)
compared to either the 6-point Mayo (59%) or patient-driven disease activity question
(59%).

Additional analysis was therefore conducted to explore why remission rates were
lower with the SCCAI than with the 6-Point Mayo (Figure 3.2A) or patient-driven disease
activity (Figure 3.2B). In patients in a remission defined by the 6-Point Mayo score,
three SCCAI questions appeared to be responsible for the discrepancy between the 6Point Mayo and the SCCAI, with over 50% of those with active disease (as defined by
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the SCCAI) answering in the affirmative to the questions: urgency, general-well being
and presence/absence of arthritis (Figure 3.2A). Similar results were seen when using
the patient-driven disease activity question to define remission (Figure 3.2B).

Correlation of patient-driven disease assessment, SCCAI and 6-Point Mayo
In the overall population, the 6-Point Mayo score was strongly correlated with the
SCCAI, with a spearman correlation coefficient (rho) of 0.71 (p < 0.0001). It was also
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strongly correlated with the patient-driven disease activity question (rho = 0.65, p <
0.0001). A similarly significant correlation was seen with the SCCAI and the single
patient-driven disease activity question with a spearman correlation coefficient of 0.66 (p
< 0.0001). When examining those patients with current or prior immunosuppressant
exposure, the correlations were similarly strong: 6-Point Mayo and SCCAI rho = 0.73 (p
< 0.0001); 6-Point Mayo and patient-driven question rho = 0.67 (p < 0.0001); and SCCAI
and patient-driven question rho = 0.66 (p < 0.0001).
Sensitivity, Specificity and ROC curves to Identify Patient-Defined Remission
Using a cut point of 1.5, the 6-Point Mayo remission score had a sensitivity of
83% and a specificity of 72% for patient-defined remission; and a sensitivity of 89% and
specificity of 67% for SCCAI remission defined as a score of < 2.5. The SCCAI had a
sensitivity of 76% and a specificity of 87% for patient-defined remission. In patients with
current or past immunosuppressant therapy exposure, the 6-Point Mayo remission score
had a sensitivity of 82% and specificity of 73% for patient defined remission; and a
sensitivity of 91% and specificity of 71% for SCCAI remission. The SCCAI had a
sensitivity of 73% and a specificity of 86% for patient-defined remission.
We defined remission using a single patient-driven disease activity question as
perfect or very good under the assumption that patients would be unlikely to seek
additional therapy if they considered themselves to have very good control of their
disease. However, we repeated the assessment of the sensitivity and specificity of the
6-Point Mayo and SCCAI defining remission as only those who answered their disease
activity as “perfect.” This resulted in a lower specificity for both scoring systems: 6-Point
Mayo sensitivity 89% and specificity 50%; SCCAI sensitivity 83% and specificity 61%.
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The ROC curves in
the total population for the
SCCAI and the 6-Point
Mayo predicting patientdefined remission are
shown in Figure 3.3A and
Figure 3.3B. The SCCAI
area under the curve was
0.87 and the 6-Point Mayo
area under the curve was
0.84 in the full population
(Figure 3.3A). In patients
exposed to
immunosuppressant
therapy, the ROC curves
showed a similar nearlyequivalent area under the
curve for SCCAI and the 6Point Mayo with an area
under the curve of 0.86
and 0.85, respectively
(Figure 3.3B).
Additional analysis
was conducted to evaluate if adding any of the SCCAI components (utilizing their
original SCCAI scaling) to the 6-Point Mayo improved the accuracy of predicting patient57

defined disease remission (Table 3.4). Two of the SCCAI components, urgency and
general well-being, significantly increased the AUC when added to the 6-Point Mayo
score (p=0.04 and p=0.0008, respectively). When both components were added to the
6-Point Mayo score, the resulting ROC area under the curve was 0.90, which was
significantly greater than the area under the curve for the 6-Point Mayo score alone
(p=0.0002). Sequential addition of both urgency and general well-being was also
performed: the addition of the SCCAI general well-being to the 6-Point Mayo already
containing the SCCAI urgency question resulted in a significant improvement in ROC
area under the curve (0.87 vs. 0.90, p=0.005); however, the addition of the SCCAI
urgency to the 6-Point Mayo already containing the SCCAI general well-being did not
reach statistical significance (0.89 vs. 0.90, p=0.16). Similar analysis was conducted
looking at those patients exposed to immunosuppressant therapy; however, in this
cohort, no SCCAI component reached a significantly improved AUC when added to the
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6-Point Mayo score (Table 3.4).

Validation Study
In the prospective I3 cohort from, 112 consecutive UC patients were consented.
Of these, 61 patients had physician-identified pancolitis (47 patients) or left-sided colitis
(14 patients) confirmed by the patient’s electronic medical record and completed the
disease severity indices without missing data. These 61 patients were included in the
validation study. Baseline demographics of this population were not significantly
different from the initial study population; however, a larger percentage of the validation
population was currently on immunosuppressant therapy (Table 3.5).
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SCCAI, 6-Point Mayo and Patient Assessment of Disease Activity
The results of the disease severity assessments for the validation survey
population are shown in Table 3.6. The percentage of patients in the total validation
population in a remission was comparable by any of the three disease activity
measurements; however, when comparing patients with pan-colitis versus left-sided
colitis, a greater percentage of patients with left-sided colitis were in a remission.
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Correlation of patient-driven assessment, SCCAI and 6-Point Mayo
In the validation population, the 6-Point Mayo was again strongly correlated with
the SCCAI (rho = 0.73, p <0.0001) and the patient-driven disease activity question (rho =
0.63, p < 0.0001). A significant correlation was also seen with the SCCAI and the single
patient-driven disease activity question (rho = 0.73, p<0.0001). When examining pancolitis and left-sided colitis subsets of the validation study, the correlations were similarly
strong. In patients with pan-colitis, the correlations were rho = 0.75, p < 0.0001 (6-Point
Mayo and SCCAI); rho = 0.61, p < 0.0001 (6-Point Mayo and single patient-driven
disease activity question); and rho = 0.70, p < 0.0001 (SCCAI and single patient-driven
disease activity question). In patients with left-sided colitis, the correlations were rho =
0.64, p < 0.0131 (6-Point Mayo and SCCAI); rho = 0.71, p < 0.0062 (6-Point Mayo and
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single patient-driven disease activity question); and rho = 0.65, p < 0.0168 (SCCAI and
single patient-driven disease activity question).
Sensitivity, Specificity and ROC curves to Identify Patient-Defined Remission
In the validation study, the 6-Point Mayo remission score (<1.5) had a sensitivity
of 90% and a specificity of 65% for patient-defined remission; and a sensitivity of 95%
and specificity of 79% for SCCAI remission defined as a score of < 2.5. The SCCAI had
a sensitivity of 85% and a specificity of 65% for patient-defined remission. The ROC
curves in the validation population for the SCCAI and the 6-Point Mayo predicting
patient-defined remission are shown in Figure 3.4. The SCCAI area under the curve
was 0.87 and the 6-Point Mayo area under the curve was 0.80.

62

Additional analysis was performed to assess if addition of individual components of the
SCCAI to the 6-Point Mayo increased the accuracy of predicting patient-defined
remission. Notably, only one patient responded affirmatively to any of the extraintestinal manifestation components of the SCCAI; therefore, ROC comparisons adding
these components could not be assessed. In the validation cohort, no component of the
SCCAI contributed significantly to improving the accuracy of the 6-Point Mayo in
predicting patient-defined remission. Based on the findings in the initial study cohort,
additional analysis was run adding both the SCCAI urgency and general well-being
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components to the 6-Point Mayo score (Table 3.7). The resulting ROC area under the
curve was 0.89, which just reached statistical significance compared to the area under
the curve with the 6-Point Mayo alone (p=0.05). Sequential addition of both urgency and
well-being was also performed and not found to be significant (p=0.09 for addition of
SCCAI general well-being to 6-Point Mayo already containing SCCAI urgency; and
p=0.37 for addition of SCCAI urgency to 6-Point Mayo already containing SCCAI general
well-being).

Ulcerative Colitis Endoscopic Index of Severity
Of the 61 patients in the validation study, 36 had a colonoscopy performed.
Three of the patients had an incomplete colonoscopy performed either due to a stricture
or disease severity; these three patients were removed from the analysis. The
remaining 33 patients had a complete colonoscopy that was retrospectively reviewed by
an external gastroenterologist and scored according to the Ulcerative Colitis Endoscopic
Index of Severity (UCEIS).129,130 Correlations between the clinical disease activity
indices and the UCEIS were overall poor: rho = 0.11, p = 0.54 (SCCAI and UCIS); rho =
0.18, p = 0.31 (6-Point Mayo and UCEIS); and rho = 0.33, p = 0.06 (single patient-driven
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disease activity question and UCEIS). The SCCAI area under the curve was 0.62 and
the 6-Point Mayo area under the curve was 0.59 (Figure 3.5).

Discussion:
In this study, we have found and validated that the 6-Point Mayo score correlated
strongly with the SCCAI and patient-reported disease activity, has a similar sensitivity
and specificity as the SCCAI for patient-reported remission, and performs equally well in
patients with more advanced disease (as defined by immunosuppressant drug
exposure) as well as patients with varying UC disease extent (left-sided colitis versus
pan-colitis). Prior studies have shown that the 6-Point Mayo score correlates well with
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patient-driven disease activity as well as both the Partial- and Full-Mayo scores.78,79 Our
study is the first to correlate and validate the 6-Point Mayo with disease activity indices
outside of the Mayo scoring system, and in patients on immunosuppression as well as
patients with varying extent of UC. Furthermore, the 6-Point Mayo score avoided the
use of cumbersome and potentially confusing questions regarding extra-intestinal
manifestations of the IBD, and thus represents a simple, efficient and effective noninvasive disease severity measurement. We have also shown that addition of one or
two questions from the SCCAI may improve prediction of the 6-Point Mayo score with
patient-defined disease activity with minimal additional burden to patients or
researchers.
In our initial study, patient-reported symptoms of urgency and general well-being,
as collected by the SCCAI, led to discrepancies between a SCCAI-defined remission
and a patient-defined remission. As these questions are not asked in the 6-Point Mayo,
discrepancies between remission as defined in the scoring systems can be expected. It
is possible that there may be points of confusion by the patients regarding each
individual question and how it relates to their UC activity: urgency in the prior three days
can be an important symptom of UC-disease; but it may also reflect irritable bowel
syndrome. General well-being can be affected by many factors outside of UC disease
activity. We also conducted additional analysis adding back these questions to the 6Point Mayo and found that they do increase the accuracy of the 6-Point Mayo predicting
patient-defined remission. Based on sequential assessment, the addition of general
well-being appears to be sufficient, and may represent a very simple addition to the 6Point Mayo.
The extra-intestinal manifestation questions in the SCCAI, specifically arthritis
and uveitis, also led to discrepancies between SCCAI-defined remission and a patient66

defined remission in the initial study. Both arthritis and uveitis are difficult to describe to
patients, and without direct physician assessment can be easily mistaken with non-IBD
related symptoms such as osteoarthritis or allergic conjunctivitis. This illustrates a
greater potential difficulty in eliciting the extra-intestinal IBD disease activity without
direct physician contact. For example, in our initial study population, a high percentage
of respondents stated they had uveitis (a relatively rare extra-intestinal complication of
IBD) in the past 3 days. Despite these differences, the c-statistic for both scoring
systems was very similar, indicating that overall, the remaining questions of stool
frequency and bleeding accounted for much of the discriminative function in both
indices. Furthermore, analysis adding back these extra-intestinal manifestations to the
6-Point Mayo did not result in improvements in the predictive ability of the scoring
system, implying that these extra variables may be unnecessary in assessing active
versus inactive disease.
Our validation study confirmed the correlation of the 6-Point Mayo score with the
SCCAI and patient-defined disease remission. It is also the first study to validate the
performance of the 6-Point Mayo score in both disease severity as well as UC disease
extent, confirming the utility of the 6-Point Mayo across a broad range of clinical
populations. Notably, in our validation population, while we did not find that the single
addition of the SCCAI urgency or general well-being improved the accuracy of the 6Point Mayo in predicting patient-defined remission, the addition of both components did
improve the 6-Point Mayo score accuracy. It is possible that the validation study was
simply underpowered to detect smaller differences at the individual component level,
and certainly additional analysis exploring this should be performed.
Additionally, in our validation study, we did not find the high reported rates of
extra-intestinal manifestations that we saw in our initial study. This may be the result of
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differences in the study populations themselves: whereas the initial study was a mailed
questionnaire, completed entirely by the patient outside of the clinical setting, the
validation study was collected in the clinical setting and during enrollment within a larger
prospective study. Unmeasured differences (recent exposure to a physician, willingness
to enroll in a clinical study, etc) may have contributed to these variations, and stress the
need for a simple, unambiguous patient-driven disease activity index.
There are potential limitations to our study. Both our initial and validation studies
were carried out using patients at one of two tertiary care centers and thus may not be
generalizable to other clinical settings. However, as such, they do represent a
commonly-utilized UC population for clinical trials and therefore a population in whom a
simple, patient-directed disease severity index would be most useful. Additionally, the
majority had extensive experience with UC, thus lending to improved validity of our
findings.
Most of the patients surveyed in both studies were in a clinically-defined disease
remission. Despite this, we did have a broad range of UC disease severity, as
evidenced by the high numbers of UC patients using immunosuppressant therapy as
well as the variations in disease extent. It is possible that the indices examined in this
study would perform differently among patients with more severe or active disease.
The indices examined in this study were for clinical remission, specifically
patient-defined remission, only. We found that none of the clinical disease activity
indices assessed (SCCAI, 6-Point Mayo or a single Likert-scale of patient-defined
disease activity) correlated well with a purely endoscopic assessment of disease
severity. Prior work has shown a good correlation with the SCCAI and an invasive index
of disease severity, the Powell-Tuck (or St. Mark’s) Index.127 However, the Powell-Tuck
Index, like many of the scoring indices in UC, is a composite of clinical, biochemical, and
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sigmoidoscopic evaluations of the patient, which may lend a greater correlation with a
clinical index (such as the SCCAI or 6-Point Mayo) compared to a purely endoscopic
evaluation. Endoscopic and histologic disease activity measures have been correlated
with important outcomes including colectomy, colorectal cancer and quality of life.75,131-134
However, in many studies, invasive disease assessment may be infeasible or serve as a
deterrent to patient enrollment. Even in studies which employ invasive disease
methods, more frequent follow-up measurements may be more easily obtained via mail,
email, or phone, without direct physician contact. Furthermore, patient-perceived
assessment of disease activity is arguably paramount in assessing quality of life which,
in turn, has effects on adherence to medical therapy. In these settings, the utility of a
simple patient-driven disease assessment tool can be appealing to researchers and
patients alike.
In conclusion, we have demonstrated that the 6-Point Mayo score, comprised of
only two questions regarding stool frequency and the presence of blood, was highly
correlated with the SCCAI and performed comparably to the SCCAI in identifying
patient-perceived clinical remission. We have further shown that addition of either the
SCCAI general well-being and/or urgency components increased the predictive value of
the 6-Point Mayo with minimal additional survey burden. Finally, we have validated our
findings in a separate UC population, and further evaluated and validated our findings in
patients of varying disease extent. Therefore, the 6-Point Mayo score represents a
simple and reproducible patient-driven disease severity index for use in observational
studies or in clinical trials without direct physician assessment.
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BACKGROUND: Therapy options for mesalamine-refractory ulcerative colitis (UC)
include immunosuppressive medications or surgery. Chronic immunosuppressive
therapy increases risks of infection and cancer, whereas surgery produces a permanent
change in bowel function. We sought to quantify the willingness of patients with UC to
accept the risks of chronic immunosuppression to avoid colectomy.
METHODS: We conducted a state-of-the-art discrete-choice experiment among 293
patients with UC who were offered a choice of medication or surgical treatments with
different features. Random parameters logit was used to estimate patients’ willingness
to accept tradeoffs among treatment features in selecting surgery vs medical treatment.
RESULTS: A desire to avoid surgery and the surgery type (ostomy versus J-pouch)
influenced patients’ choices more than a specified range of 10 y mortality risks from
lymphoma or infection, or disease activity (mild vs remission). To avoid an ostomy,
patients were willing to accept a greater than 5% 10-year risk of dying from lymphoma or
infection from medical therapy, regardless of medication efficacy. However, data on
patients’ stated-choice indicated perceived equivalence between J-pouch surgery and
incompletely effective medical therapy. Patient characteristics and disease history
influenced patients’ preferences regarding surgery vs medical therapy.
CONCLUSIONS: Patients with UC are willing to accept relatively high risks of fatal
complications from medical therapy to avoid a permanent ostomy and to achieve durable
clinical remission. However, patients’ view J-pouch surgery, but not permanent
ileostomy, as an acceptable therapy for refractory UC in which medical therapy is unable
to induce a durable remission.
72

Keywords: inflammatory bowel disease, IBD, DCE, maximum acceptable risk

73

INTRODUCTION:
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that can be
severely debilitating, and has no medical cure. Historically, UC was treated with
mesalamine and corticosteroids; and if these failed, surgical resection of the colon.
Because UC is limited to the colon, surgery offers a theoretical “cure” and eliminates the
risk of colon cancer. The two most common operations performed are a total
proctocolectomy with end ileostomy and restorative ileal pouch anal anastomosis
(IPAA). The former entails a permanent ileostomy while the latter avoids this but is
associated with frequent bowel movements and the risk of fecal incontinence.
The demonstrated efficacy of thiopurine analogues and antibodies against tumor
necrosis factor α has improved our ability to induce and maintain remission. However, at
least one-third of patients will fail to produce a durable remission.41,135,136 These patients
will often be exposed to repeated or chronic corticosteroid therapy which is associated
with increased morbidity and mortality.20,21,23 Furthermore, chronic immunosuppressant
maintenance therapy risks serious and opportunitistic infections,21,26,137 and an
increased the risk of certain cancers including lymphoma30,31 and hepatosplenic T-cell
lymphoma.138,139
If surgery for UC resulted in a completely normal quality of life, the choice
between medical and surgical therapy would be obvious. Because this is not the case,
physicians and their patients are willing to accept risks of medical therapies, often with
the presumption that the patient’s foremost desire is to avoid surgery. However, for
some patients this may not be the case; and in an era that places an increasing premium
on patient autonomy and shared decision making, quantifying UC patients risk
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preferences includes their voice in an increasingly complex decision process.
Furthermore, quantifying patients’ risk threshold can help physicians, drug
manufacturers and regulators when contemplating appropriate indications for existing
and new medical therapies. Prior studies evaluating UC patients’ preferences have been
few and employed methodologies that make numerous uncertain or inaccurate
assumptions about patient preferences.50,61 In this study, we used an innovative patientpreference methodology called discrete-choice experiment (DCE) to quantify the UC
patients’ tolerance for life-threatening serious adverse events (SAEs) in exchange for
specific treatment benefits. We estimated the mean maximum acceptable risk (MAR) for
SAEs associated with immunosuppressant therapy in UC that patients are willing to
accept to avoid colectomy with ostomy, IPAA or IPAA complicated by fecal incontinence.
We also evaluated how clinical characteristics affect tolerance for medical therapy risks
in preference to surgery.
MATERIALS AND METHODS:
DCEs, also known as choice-format conjoint analysis, quantify strength of
preferences for features of products, services, or health-care interventions and are
increasingly being applied in the health sciences.67,140,141 Interventions, such as medical
or surgical treatments, derive value from their specific attributes, features or outcomes
including treatment efficacies and potential SAE risks. Each of these attributes can
occur at varying levels, such as remission rates or SAE incidence. DCEs recognize that
patients have preferences of varying strengths for different attributes and are willing to
accept tradeoffs among various levels. By systematically eliciting tradeoffs among
constructed outcome combinations, DCEs generate choice data to quantify implicit
decision weights indicating relative utility or satisfaction that patients have for both
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individual attributes of a treatment (such as the specific risks and benefits) as well as the
treatment as a whole. Because DCEs measure the rate at which patients accept
tradeoffs among different treatment attributes, it is possible to use these trade-off rates
to scale a change in one attribute to equivalent units of another attribute. It is thus
possible to calculate time equivalents, money equivalents, and risk equivalents of a
given change in treatment options. In this study, we used estimated trade-off rates to
calculate the MAR as an indication of patients’ willingness to accept medication-related
SAE risks to avoid surgery.
Survey Development
A DCE survey instrument was developed using best-practice methods142 to elicit
patients’ willingness to accept tradeoffs among therapeutic options regarding medical
and surgical interventions for UC. The survey instrument assessed respondents’
baseline demographics, current disease activity (using the Simple Clinical Colitis Activity
Index (SCCAI) and 6-point Mayo score),79,126 medication use history and knowledge of
colectomy surgery. Numeracy was assessed using test questions.
For the DCE scenarios, attributes were determined from a literature review, IBD
expert consultation, focused interviews with IBD patients and a pilot study in 127 UC
patients. On the basis of this information, a decision frame was developed in which
respondents assume a moderate-to-severe UC flare and must select either a new
medication or surgery as treatment for the flare (Table 4.1). Medication treatment
attributes included efficacy with levels of remission and incomplete response resulting in
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mild disease activity for 10 years, described using text from the Mayo score.128

Surgery was described as a one- or two-step process with a resultant permanent
surgical remission. A permanent ostomy (single stage operation) was described as
having a surgical remission with no blood, abdominal pain, fatigue or interference with
job/daily activities and having bowel movements through the ostomy. Pictures of female
and male patients with ostomy bags were shown. Two-stage (IPAA) surgery was
described as resulting in an average 5 bowel movements per day but otherwise having
similar disease-activity symptoms as those having an ostomy. Incontinence also was
described. All surgery was described as carrying a one-in-three chance of having
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difficulty becoming pregnant for female patients. Pilot testing indicated good
understanding of the medical and surgical outcomes.
For non-surgical options, a 0.3% risk of dying from colon cancer within 10 years
was included.143 Two SAEs were additionally considered. The risk of dying from
lymphoma was only associated with selection of medication therapy; the risk of dying
from a serious infection was associated with both medication therapy and surgery.
Colorectal cancer, lymphoma and serious infections were described using layman terms
based in part on descriptions from the American Cancer Society patient information144.
For each of the SAEs, hypothetical risk levels ranged from 0% to 5% for experiencing
the event within the next 10 years. Pretest interviews and pilot data indicated that this
range yielded trade-off information required to quantify MAR. The 10-year time frame
was determined to be appropriate during piloting and data collection/analysis from
conceptual, methodological and patient-cognitive perspectives. Pretests of the
instrument found that 10 years allowed for magnification of annual risks to levels that
could be described graphically and were sufficiently salient to induce tradeoffs among
other attributes.
To limit cognitive burden and numeracy concerns, all treatment benefits were
described as certain and all treatment risks were described as known probabilities. To
avoid measurement error in preference elicitation and analysis, specific risk levels
(rather than ranges) were presented in keeping with best practice methods.142 To further
aid respondents understanding of quantitative risks, the SAE probabilities were
presented in three ways: graphically as a risk grid of shaded circles indicating the
number of patients out of a full grid of 1000 circles who would die from the SAE; and
numerically as fractions (counts out of 1000) and percentages (Figure 4.1).
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The DCE questions in the final survey instrument asked patients to choose
between a medication resulting in either complete remission or incomplete remission
(i.e. mild disease activity) for 10 years or surgical therapy for their UC disease flare.
Figure 1 is an example of the DCE question format. We used a variation of a commonly
used algorithm in SAS to construct a D-efficent experimental design resulting in 48 pairs
of treatment options.145-149 To reduce respondent burden, the trade-off scenarios were
blocked into 6 sets of 8 questions. Each participant was randomly assigned to receive 1
of the 6 sets of questions. Surveys were mailed using the Dillman method to maximize
response rates.150
Survey Validation
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The design of the DCE survey included tests for numeracy and an internal test
for subject-level validity through logic testing. To assess numeracy, subjects were
shown a series of numerical examples of risk, presented as percentages, fractions and
an illustrative risk grid, and subsequently tested on their understanding of these numeric
concepts. Logic testing was assessed to evaluate if respondents understood the
question-choice format sufficiently to indicate a preference for a visibly better therapy
through an additional trade-off scenario in which medication treatment dominated the
surgical treatment for every attribute. The model was tested to evaluate the statistical
influence of respondents who failed one or both of these tests.
Survey Sample
Patients were eligible if they were ≥ 18 years of age with an ICD-9 code for UC
(556.0-556.6 and 556.8-556.9) and an outpatient gastroenterology clinic visit at
participating institutions within the prior two years. Patients with any ICD-9 code for
Crohn’s disease (555.0-555.2, 555.9) were ineligible. In the survey, patients were asked
if they considered themselves to have UC; only respondents who further self-identified
as having UC were included in the survey sample. All patients received a small financial
compensation for their time and effort.
Statistical Analysis
In DCE studies, the pattern of choices by respondents observed reveals the
implicit decision or preference weights respondents used to evaluate the hypothetical
treatment tradeoffs. Multivariate random-parameters logit was used to estimate
preference weights for each attribute level while avoiding potential estimation bias in
choice models from unobserved variation in preferences not accounted for by the
variables in the model.151,152 Both a mean value and taste-distribution standard-deviation
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parameter are estimated for each preference weight. A flexible correlation structure also
accounts for within-sample correlation in the question sequence for each participant.
Effects coding was used so that the mean effect of each attribute is normalized at
zero instead of setting all the omitted categories to zero. The omitted-category
parameter is the negative sum of the included-category parameters for each attribute.
This provides a parameter estimates for every attribute-level preference weight, avoids
confounding the grand mean with marginal effects, and facilitates subsequent
calculations. T-statistics thus are interpreted relative to the mean effect rather than the
omitted category.
The resulting mean preference weights are used to estimate the MAR, the
maximum acceptable risk, defined as the specific increase in treatment risk that exactly
offsets the therapeutic benefit of a given improvement in treatment outcomes. For
example, consider a medication A that has a measured therapeutic benefit β1 = 0.5
(versus surgery); and a value of βi = -0.025 for each 1% increase in infection risk. The
MAR for medication A is the increased risk of infection that exactly offsets the increase
in satisfaction from preserving one’s colon. Since offering medication A increases
patients’ satisfaction by 0.5 versus surgery, if medication A increases the risk of infection
by 0.5/0.025 = 20%, then the increased infection risk exactly offsets patients’ perceived
satisfaction from avoiding surgery. However, if medication A increases the risk of
infection by <20%, then patients would be better off with medication A than with surgery.
In practice, risk levels are fit to a generalized nonlinear function to utilize all information
regarding the shape of the response gradient when determining the level of risk that
makes the mean preference weight = 0 between categorical risk-level parameters.
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In our model, certain attributes were applicable only to the medication or surgical
therapy option. Furthermore, the surgical therapy option was inherently different from
the medication therapy option. Interaction terms and constraints in the model account
for and measure the effect of surgery versus medical therapy in choice preferences for
attributes. The goal of the survey instrument was to calculate respondents’ willingness
to trade off risk of SAE for improvements in UC symptoms through either medical or
surgical therapy by calculating the MAR which respondents were willing to accept from a
given medical therapy of specified efficiency to avoid a specific surgical outcome.
Comparisons were made of the MARs for the lymphoma and serious infection SAEs in
exchange for treatment efficacy to avoid surgical outcomes of an ostomy, a J-pouch with
incontinence and a perfectly functioning J-pouch. When computation of MAR required
extrapolation beyond the upper level of risk presented in the survey, we report risk
tolerance as greater than the level of risk shown.
Overall joint tests of parameter differences employed the scale-controlled
likelihood-ratio test for choice models.153 Tests of differences of MARs used 2-tailed ztests for differences of means for independent, normally distributed random variables.
Statistical differences between individual parameter estimates were tested using
maximum-likelihood asymptotic 2-tailed tests at the 95% confidence level. Subgroup
analysis was performed utilizing an effects-coded model that included an interaction
term with the most preferred parameter to maximize the statistical power of the subgroup
models. SAS 9.2 was used for data management and tables. Limdep/NLOGIT 7.0 was
used for statistical modeling.
ETHICAL CONSIDERATIONS:
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The study and final survey instrument were approved by the Institution Review Boards at
participating institutions.
RESULTS:
Survey Population
Survey instruments were mailed to 662 patients and responses were received
from 374 patients (56% response rate). We had limited information on non-responders,
but men were less likely to respond (data not shown). Eight respondents (3%) answered
the numeracy questions correctly but failed a test scenario in which there was a clearlydominated treatment choice. Given the small number and their appropriate response to
the numeracy questions, these patients remained in the analyzed final sample. After
applying the exclusion criteria and excluding patients with missing answers to conjoint
questions, 293 respondents were included in the final analysis (Fi
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gure 4.2). Baseline demographics are shown in Table 4.2. Notably, the majority of
respondents was highly educated and had a long-standing history of UC. Over half were
in a remission as defined using the SSCAI or 6-point Mayo score. The majority of
respondents had previously or was currently taking an immunosuppressant medication,
inclusive of thiopurine analog, calciurin inhibitor, methotrexate and/or anti-TNFα (Table
4.2).
Table 4.2: Summary of Patient Characteristics*
Characteristic
Gender, n (%)
Female
Male
Age
Median
Mean
Site n(%)
Dartmouth-Hitchcock Medical Center
Hospital of the University of Pennsylvania
Ethnicity/Race n(%)
Caucasian
African-American
Asian
Latino
Other
Highest level of completed education, n (%)
Less than high school
High school or equivalent
Less than four years of college
4-year college degree (e.g., BA, BS)
Post-graduate studies
Marital status, n(%)
Single/Divorced/Widowed
Married
Desire for children, n(%)
Would like to have children in future
No desire/plans to have children in future
Smoking status, n (%)
Current smoker
Past smoker
Never smoked
Length of time with UC
1+ years, n (%)
Mean, years
Median, years
Currently having active UC symptoms, n(%)
When last active UC symptoms were experienced, n(%)
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Patients
(N = 293)
166 (57)
127 (43)
45 years
47 years
20 (7)
273 (93)
256 (87)
17 (6)
9 (3)
2 (1)
4 (1)
1 (<1)
32 (11)
59 (21)
91 (32)
99 (35)
94 (33)
189 (67)
80 (28)
202 (72)
15 (5)
105 (38)
160 (57)
293 (100)
13
10
75 (27)

Currently or within last 3 months
3-6 months ago
6 months to one year ago
Greater than one year ago
Simple Clinical Colitis Activity Index < 2.5
6-point Mayo score < 1.5
5-ASA (oral and/or rectal)
Current use
Past use
Corticosteroids (oral and/or rectal)
Current use
Past use
Azathioprine/6-MP
Current use
Past use
Cyclosporine and/or tacrolimus
Current use
Past use
Methtrexate
Current use
Past use
Anti-TNF therapies (infliximab, adalimumab, certolizumab)
Current use
Past use
Current or past immunosuppressant use (azathioprine, 6MP, cyclosporine, tacrolimus methotrexate, anti-TNF)
Personal history of serious infection requiring
hospitalization
Knew family member and/or friend with serious infection
requiring hospitalization
Personal history of colorectal cancer
Knew family member or friend with colorectal cancer
Personal history of lymphoma
Knew family member or friend with lymphoma
Personally had history of bowel surgery with ostomy
Knew family member or friend with ostomy bag
Never discussed surgical options with medical or surgical
physician
Believe colonoscopies will prevent colorectal cancer
*Missing data excluded for each category

70 (25)
38 (14)
41 (15)
131 (47)
56%
64%
57%
83%
10%
70%
16%
29%
2%
2%
<1%
3%
15%
22%
54%
19%
23%
1%
36%
2%
19%
13%
17%
51%
74%

Preference Weights
Analysis of respondents’ preference weights for the varying levels of mortality
from lymphoma or serious infection over 10 years indicated a relatively steep decrease
in DCE utility for all attributes when going from 0% to 0.5% risk compared to equivalent
increments in levels of risk beyond 0.5% (Figure 4.3A). This result is inconsistent with
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the conventional preference-elicitation methods which assume linear preferences across
probabilities; and indicate that participants perceived a much larger decrease in utility
from going from “no risk” to “some risk” (such as 0.5%) than they did from moving from
“some risk” to “some additional risk” (such as 2% or 5%). Other researchers have
identified similar risk-preference nonlinearities in non-health and health applications.61,62
Figure 4.3B shows the relative preference-weight estimates for the risk attributes
and medication efficacy. The estimated preference weights for risks and efficacies are
consistent with the natural ordering of the levels. The largest effect on DCE utility was
for the difference between a J-pouch and ostomy when the participant selected the
surgery option: no other change in risk levels was comparable to the perceived benefit of
avoiding an ostomy when surgery was chosen as the preferred therapy for a UC flare.
This difference in surgery type—J-pouch versus ostomy—influenced patients’ choices
more than the risk of dying from lymphoma or serious infection, or medication efficacy
over the ensuing 10 years when the medical therapy was chosen. At the other extreme
was medication efficacy: the difference between a medication-induced remission and an
incompletely effective medication that only improves disease activity to a mild state was
roughly equivalent only to the difference between a 0% risk of lymphoma and a 0.5%
risk. Thus, on average, patients were willing to accept a 0.5% increase in risk of dying
from lymphoma over 10 years if the medication put them in a complete remission.
However, if the risk of lymphoma mortality over 10 years were higher, patients preferred
a less effective medication with 0% risk of lymphoma.
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The mean MAR estimates of tolerance for SAE mortality risks respondents were
willing to accept for better surgical or medication outcomes are shown in Table 4.3. To
avoid having an ostomy, patients were willing to accept more than 5% risk of dying from
lymphoma over 10 years even if the medication was incompletely effective. In contrast,
patients were willing to accept only a 1-1.6% risk of death from lymphoma or serious
infection for improved medication efficacy. Patients were less tolerant of medication risk
if the surgical outcome was a J-pouch; and remarkably, patients were equally satisfied
with J-pouch surgery as with an incompletely effective medical therapy that left them
with mild disease symptoms over 10 years (Table 4.3).

Effect of Covariates on Benefit-Risk Tradeoff Preferences
Subgroup analysis was performed utilizing an effects-coded model and
implementing an interaction on the most preferred parameter (Figure 4.4). Disease
duration, time from last flare (< 3 months) and disease activity overall had no impact on
preferences for surgical versus medical therapy. There was a small subgroup of patients
currently on immunosuppressant therapy who reported current active disease symptoms
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(n=23), thus representing a compelling sample of patients facing possible surgery.
Compared to those not on immunosuppressant therapy, these patients were less willing
to accept ostomy surgery (p=0.04), but also less willing to accept the risk of lymphoma
with medical therapy (p=0.03). These findings are consistent with our overall findings of
equivalent satisfaction with J-pouch surgery (but not ostomy) in the face of ineffective
medical therapy and seem to indicate an influence of disease history on risk tolerance.
Desire to have children did not influence the preference for surgical versus
medical therapy; but females were significantly less willing to accept ostomy surgery
(p=0.03). Prior knowledge of the attributes did influence preferences: patients with either
personal or first-hand knowledge of colectomy surgery were more willing to accept
surgery overall (p=0.002) and less willing to accept ineffective medical therapies
(p=0.007). Those first-hand knowledge of serious infection, colon cancer or lymphoma
were also more willing to accept surgery overall (p=0.006), although they were also less
willing to accept ostomy as an outcome (p=0.02). Additionally, those patients who had
discussed surgery with a surgeon or physician were significantly more willing to accept
surgery overall (p=0.03).
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Impact of numeracy skills on results
Twenty-nine patients (9%) failed one or more of the numeracy tests. These
patients were excluded from the overall sample of 293 and assessed separately. This
group was significantly older than the baseline sample (median age 70 years), and 21%
were African-American or described their race/ethnicity as “other.” 54% had a highschool/GED education or less; only 22% had a 4-year college or higher education. More
were prior smokers (58%) and fewer (39%) had never smoked. Finally, a large
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percentage (83%) stated they had never discussed surgical options for their UC with a
surgeon or physician; and this low-numeracy group expressed a stronger preference to
avoid surgery compared to the remainder of the population (p=0.02, data not shown).

DISCUSSION:
To our knowledge, this is the first study utilizing DCE to quantify patients’ tradeoff preferences for life-threatening adverse medication risks, surgical options and
symptom relief in UC. Using DCE, we found that patients were willing to accept high
levels of serious adverse risk from medical therapy to avoid an ostomy. However,
patients also valued medication efficacy; indeed, if a durable clinical remission could not
be achieved with medical therapy, patients were equally satisfied with J-pouch surgery.
To our knowledge, this is the first empirical demonstration that UC patients without prior
surgery view a well-functioning J-pouch as equivalent to persistent mild disease activity.
Our results have several important implications. First, patients expressed a
willingness to accept tradeoffs among treatments of varying efficacies, risks of
associated SAEs and surgical options in their responses to the DCE scenarios. As
expected, patients’ choices indicated a systematic preference for lower risk of SAEs and
improved medication efficacy. However, the preference to avoid surgery or SAEs
outweighed concerns regarding medication efficacy. During piloting, one-on-one
interviews elicited a repeated sentiment that a disease flare associated with
corticosteroid use was “acceptable” because it was a previously experienced risk,
whereas the risks of a lymphoma, serious infection or surgery were much less familiar.
The sentiment that rarer or poorly-understood risks are worse than more familiar risks is
a well-studied phenomenon and the consistency of our results with this literature
supports the face validity of our findings.154
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Second, patients expressed a willingness to accept extremely high risks of SAEs
to avoid a permanent ostomy or complications of a J-pouch. However, not all surgical
options were so strongly disregarded in preference for medical therapy: UC patients
were equally satisfied with an uncomplicated J-pouch surgery as they were with medical
therapy, especially if that medical therapy was incompletely effective in maintaining a
sustained remission (normal number of daily stools without blood or abdominal pain; and
a good functional status without interference with work/daily activities) for 10 years. To
the best of our knowledge, this is the first documentation of such a finding in UC.
Our study’s finding that UC patients are willing to accept surgery as a treatment
option for their disease is novel and has several important implications. First, it highlights
that patient preferences can vary significantly from providers’ assumptions regarding
these preferences. Current treatment algorithms have rested on the assumption of UC
patients’ aversion to all surgical options; and indeed, prior conventional risk-assessment
in UC supported this finding.50-54 Our findings underline the need for rigorous
methodologies to accurately measure patient-preferences, and present several potential
areas for further inquiry regarding UC patient preferences’ for their disease. As noted
below, these findings and our methodological approach also have implications for
diseases beyond UC, where physicians often make assumptions about patient
preferences for risks and therapies in the absence of guiding data.
Second, our study illustrates a critical unmet need in treatment discussions with
UC patients. Shared decision-making and informed consent have increasing importance
in the changing treatment algorithms for IBD.155 The majority of GI providers will
escalate medical therapy for their UC patients due to failure of mesalamine to ensure a
durable remission.8,14 However, our survey indicated that approximately 50% of patients
with UC had never discussed surgical options for their UC with either a medical or
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surgical physician, including 39% of patients with current or past immunosuppressant
therapy use (data not shown). Despite this, nearly 75% of our population indicated they
felt they understood their surgical options very well or had minimal questions regarding
surgery for UC (data not shown), indicating attainment of information from sources
outside of their IBD care providers. Therefore, our findings that UC patients overall were
willing to accept J-pouch surgery when faced with incompletely effective medical therapy
clearly indicates a potential unmet need in treatment discussions with UC patients by all
providers. Given the low surgery-discussion rate in our sample, our findings could also
under-estimate UC preferences regarding surgical therapy, which may further bolster the
importance of both discussions with patients and the acceptability of surgical options.
Finally, this finding has important implications for testing efficacy of novel
therapies. These data suggest that for a medication to be preferred over J-pouch
surgery, it needs to achieve sustained remission, not just a clinical response. As such,
remission may be the preferred outcome for testing efficacy of new therapies.
We also found that clinical history did influence preferences for therapies,
including current and prior disease course, gender, knowledge of the attributes and
discussion of surgery with a care provider. It is important to note, however that the study
design was not powered for precise sub-group analysis (as indicated by some large but
non-significant ratios in the subgroup analysis Figure 4.4). Given variable distribution of
potential clinical characteristics, it is possible that other meaningful differences could not
be discerned.
DCE has significant advantages over other approaches to preference
assessment. Simple survey instruments which ask patients for their willingness to take
medications fail to take into account alternative therapies or outcomes if the therapy is
not taken. Simple Likert-scale questions on the importance of separate interventions or
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outcomes do not provide data on clinically relevant trade-off evaluations required in
actual treatment decisions. DCE mimics such actual decision-making by requiring
respondents to evaluate tradeoffs in a realistic, although hypothetical, choice context.
Alternative techniques such as standard gamble or time trade off elicit preferences for
clinically unrealistic tradeoffs and assume that preferences are linear in time, linear in
probabilities and identical across groups of patients, not allowing for health history or
current health state to affect the relative importance of outcomes. Our current study has
shown that such assumptions are inaccurate for UC patients.
Our results are subject to several potential limitations and qualifications. DCE is
a simulated decision-making experience using hypothetical therapeutic options and
therefore do not have the same medical, emotional and financial consequences of actual
therapeutic decisions. Therefore, patients may be more or less willing to accept risks in
an actual clinical setting. We sought to minimize this limitation with a series of patientlevel interviews and intense piloting to make the DCE trade-off scenarios as realistic as
possible.
The exercise of evaluating tradeoffs among multiple therapy options with multiple
endpoints may be congnitively challenging. However, we assessed the validity in
participant responses through numeracy and logic tests, and the majority of our
respondents (over 90%) passed these evaluations. In particular, our study population
had extensive experience with UC, was overall well-educated, and included a large
proportion with personal knowledge of many of the attributes, thus strengthening the
validity of their preferences of choice options in the DCE survey. However, in our study,
those participants who failed the numeracy exams had essentially uninterpretable
results. Therefore, extrapolation of our results to low-numeracy populations should be
done with caution.
94

Our patients were seen by a variety of physicians from tertiary-care centers; and
the majority had escalated medical therapy. While this may limit generalizability, our
sample would seem to typify the UC patient who has exhausted 5-ASA therapies and
now faces decisions regarding immunosuppressant use versus surgery for further UC
flares. Many of these patients are seen by community and local practices; thus, our
findings have applicability beyond referral centers.
Both SAEs associated with medical therapies and surgical outcomes are
probabilistic in the real clinical setting. However, in piloting, including conditional
probabilities (the probability of an SAE conditional on the probability of having the
outcome) led to significant patient confusion. This was likely related to known difficulties
with conditional-probability numeracy skills in the general population. Therefore, to
minimize this bias, we presented surgical outcomes as certain and presented SAEs as
mortality associated with the SAEs. Our estimates therefore cannot be interpreted as
MARs for uncertain benefits or outcomes at the individual patient level, and therefore
must be interpreted with caution. However, we sought to evaluate the MARs over the a
plausible distribution of potential SAEs related to medical therapy, or over the potential
distribution of surgical outcomes, so that despite these simplifying assumptions, these
aggregate estimations may be informative for decisions regarding benefit-risk tradeoffs
for populations of UC patients.
Similarly, the outcome of pouchitis is a conditional outcome of J-pouch surgery;
and is further conditional in its chronicity with some having an isolated episode while
others have a more chronic course. To avoid such complicated calculations, we chose
not to include the risk of pouchitis as an attribute. However, we did include incontinence
which may serve as a surrogate for some of the clinical symptoms of pouchitis (including
bowel frequency and incontinence). To the extent that fear of pouchitis might dissuade
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patients from having pouch surgery, the MAR for infection and lymphoma relative to
pouch surgery could be viewed as underestimates. However, for these patients,
incontinence would be expected to be a worse outcome than pouchitis, and therefore the
estimated MAR for J-pouch surgery with pouchitis can be extrapolated to fall between
incontinence and a perfectly-functioning J-pouch.
Our attributes were within a 10 year time horizon for both risks and efficacy. This
helped to avoid requiring respondents to interpret extremely small probabilities.
Furthermore, when medical therapies such as thiopurines or anti-TNF therapy are
initiated, the plan typically calls for chronic therapy as long as the medication remains
effective. Similarly, colectomy is irreversible. Although assuming that UC would remain
in remission or mildly active for a full 10 years is an over-simplification of the natural
history of medically treated UC, one can view these results as if the average disease
activity was mildly active or inactive for the 10 year period. Thus, the 10 year time
horizon presented in this discrete choice model provided for improved patient
understanding and was consistent with the time frame appropriate for the clinical
decision.
In conclusion, we have applied a novel methodology to quantify UC patients’
treatment preferences with striking findings. Patients preferences are most strongly
impacted by the type of surgical outcome: patients are willing to accept medications that
have relatively high risks of fatal complications to avoid a permanent ostomy or
incontinence. Our findings therefore lend quantifiable evidence that support current
treatment paradigms that involve pursuance of medical therapies to avoid these surgical
outcomes. This rigorous methodology also can aid regulators in understanding patients’
evaluation of the risk of SAEs for future medical therapies in the context of potential
therapeutic benefit.
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Even more striking, however, UC patients are equally satisfied with an
uncomplicated J-pouch as they were with a medication that has very small risks of fatal
complications or a medication that is incompletely effective at sustaining a durable
clinical remission. Traditionally, clinical trials of new therapies have evaluated two
endpoints--clinical response and clinical remission. Our findings indicate that when
evaluating new therapies or therapeutic algorithms, the primary outcome should be a
clinical remission rather than a clinical response. Given that patients are equally satisfied
with surgery as with mild disease activity, and the goal of medical therapy is to achieve
greater patient satisfaction than with surgery, our findings also indicate a critical unmet
need to improve physician-patient communication regarding realistic expectations of
medical and surgical therapies.

97

CONCLUSIONS
UC represents a unique type of IBD in which there is the potential for a cure;
however, this is a surgical cure with an imperfect quality of life. The past few decades
have seen an increasing array of immunosuppressive medical therapies for UC, and the
upcoming years bring promise of additional such therapies. Inherent in the development
of these therapies, and in current treatment paradigms, is the assumption that UC
patients’ prefer to avoid colectomy surgery at all costs. However, as medical therapy in
UC has continued to progress, so has the appreciation for the SAEs associated with
these therapies as well as the inconsistent durable efficacy of these therapies for a
lifelong disease. This begs the question, “What if medical therapy is not right for
everyone? At what point are UC patients unwilling to accept chronic medical therapies
for their UC, and more willing to accept a surgical cure?”
To address this question, traditional patient risk tolerance studies have been
conducted with results that would support the notion that UC patients view colectomy
surgery as an option of last resort. However, these traditional methods for measuring
risk tolerance have inherent flaws that may bias their estimates of patient preferences.
While economic theory has advanced the methodologies used to quantify utility
estimation and risk-benefit tolerance, these advanced methodologies have not been
applied to the question of medical versus surgical therapies in UC. We recognized that
such studies are critical in this field, where current treatment guidelines rest solely on
such assumptions of patients’ intolerance for surgery; and where the risks of chronic
medical therapy can have life-threatening consequences. We therefore sought to apply
DCE to accurately quantify UC patients’ risk-tolerances for medical and surgical therapy
in their disease.
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We began by defining all-cause and cause-specific mortality in UC in the most
comprehensive meta-analysis performed to date. Our findings are the first to
demonstrate an increased all-cause mortality rate relative to the general population, a
finding that itself is worthy of additional investigation. We also found increased causespecific mortality from CRC, pulmonary disease and nonalcoholic liver disease in UC.
Further investigation is warranted to elucidate specific causes of these elevated mortality
rates. To this end, we have conducted initial analysis in the area of overall mortality with
a study comparing relative survival of UC patients with moderate-severe disease
pursuing chronic medical therapy versus elective colectomy surgery. Our finding of an
increased mortality in UC patients with moderate-severe disease pursuing chronic
medical therapy supports earlier limited studies addressing this question, and raises
important questions about the two treatment strategies, especially in the setting of the
findings from our DCE work.38,39,156
Additional studies are also needed aimed at evaluating pulmonary-related and
liver-related mortality. It is interesting to note that CD patients in particular also had an
elevated liver-related mortality. Traditionally, liver-related disease in IBD was believed to
be secondary to primary sclerosing cholangitis (PSC), a rare disease most commonly
associated with UC. It is possible that the elevated liver-related mortality is not
exclusively due to PSC but perhaps due to other causes of liver disease. Those with
IBD are also at risk for liver diseases that affect the general population. The most
common of these conditions is that of non-alcoholic fatty liver disease;121 and recently
there has been an intriguing association between visceral fat and IBD, specifically CD
activity.157,158 These findings raise the question of whether fatty liver disease is a cause
or a consequence in IBD. Specifically, it is possible that active IBD increases visceral
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and hepatic fat. We are currently conducting analysis to investigate underlying rates of
non-alcoholic fatty liver disease in IBD and correlate it with disease activity and
increased visceral adiposity. Pulmonary-related mortality in IBD may be related to lack
of tobacco cessation in this population; or related to increased pulmonary-related
infections, especially in the setting of increased immunosuppressant use. Results from
further studies investigating these potential causes of elevated mortality in CD and UC
could inform improved interventions such as vaccines, dietary therapies, or even
improved informed consent for IBD patients when making decisions regarding therapy
options for their disease.
While not the primary purpose of our meta-analysis, our study also demonstrated
that inception-based cohorts and population-based studies yielded very similar overall
mortality estimates in IBD. It has been widely believed that inception-based cohorts
were superior to population-based studies in evaluating mortality. Our findings suggest
the potential for greater inclusion of population-based studies in these investigations,
which may allow for data enrichment from cohorts not otherwise utilized.
Assessing disease severity in UC without direct physician contact was critical to
our DCE study. Non-invasive clinical disease assessment has been a challenge, due to
cumbersome and complicated patient-driven disease activity indices such as the SCCAI.
We evaluated a simple 2-question patient-driven non-invasive disease activity index, the
6-Point Mayo, and found it to have good correlation, sensitivity, specificity and predictive
value compared to the SCCAI. We further validated this in a separate cohort of UC
patients and found similar results even when stratified by varying disease extent
(pancolitis versus left-sided colitis). Finally, we conducted analysis adding back
components of the SCCAI to determine if the 6-Point Mayo could be improved with any
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single SCCAI component. We found that the components of urgency and general wellbeing improved the 6-Point Mayo’s predictive value. Overall, these supplemental SCCAI
components contribute very little additional burden to the 6-Point Mayo, thus allowing
clinical investigators a simple non-invasive tool to assess disease activity without direct
physician contact. With the increasing number of clinical studies in UC, this promises to
be a very important tool for researchers.
In our study, we did find a poor correlation between the non-invasive patientdriven indices and a purely endoscopic evaluation of UC disease activity. It is wellknown that endoscopic, and even histologic, active disease is often found in patients
who are asymptomatic. With an increasing awareness of the importance of mucosal
healing in IBD, this disconnect between patient symptoms and endoscopic activity leads
to important future questions. It is likely that different parameters govern patients’
willingness to accept additional medical therapy risks to improve mucosal healing and
presumably prevent future disease relapses, especially in the setting of asymptomatic
clinical disease. We are currently conducting DCE analysis evaluating patients’ risk
tolerances in this setting. The findings of this study will have important impact in therapy
algorithms for IBD patients, including defining potential thresholds for therapy efficacy
and SAEs to achieve mucosal healing.
Finally, we have conducted the first DCE study evaluating UC patient risk
tolerances for medical therapy SAEs to avoid colectomy surgery with varying treatment
efficacy. We have shown, for the first time, that when facing incomplete durable clinical
remission with medical therapy, UC patients are equally willing to accept J-pouch
surgery. Additionally, this study illustrates that UC patients do value the difference
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between remission and clinical response, and suggests that the former should be the
preferred outcome when evaluating therapies in UC.
Our work emphasizes that UC patient preferences for disease therapy can vary
significantly from providers’ assumptions regarding their preferences; and questions the
traditional therapy algorithm in UC of exhausting all medical therapy before considering
colectomy surgery. Taken together with increasing evidence that elective colectomy
may have a survival benefit in moderate-severe UC,38,39,156 the current work supports
early discussion regarding surgical options for UC patients. In our current work, the
majority of UC patients indicated a lack of discussion regarding surgical options for their
UC in their current medical care, a finding previously supported by other studies.159-161
There are several possible reasons for this. UC patients may reject considering surgery
as a valid option due to pre-formed notions regarding surgery in general.
Gastroenterologists may not have time to discuss surgical options for their patients, and
may make it a low priority in therapy discussions. This may be especially true given the
traditional view held by gastroenterologists that UC patients want to avoid surgery at all
costs. Finally, gastroenterologists may not sufficiently or accurately depict surgery in a
way that makes UC patients comfortable with their discussion. In our prior work, we
examined what factors were associated with UC patients reporting that they “felt very
comfortable with their understanding of the surgical options for their UC and had no
further questions regarding surgery.” The only statistically significant variable associated
with UC patients reporting satisfactory understanding with UC surgery was discussion
with a surgeon—not a gastroenterologist.159
Our work has therefore illustrated a critical unmet need for improved surgical
education and discussion in UC. If UC patients are averse to the risks of medical
102

therapy, but lack sufficient knowledge about the surgical options for their UC,
educational interventions are crucial to facilitate shared decision-making and informed
consent. One of the most important roles of education is to help patients weigh medical
therapy risks against the risks of surgical therapy. This informed decision-making has
even greater value in the setting of incompletely effective medical therapy that risks
continued active disease. Education could alter patients’ readiness to choose colectomy
instead of medical therapy. This takes on even greater impact given the potential for
improved survival with elective colectomy compared to chronic ineffective medical
therapy, which entails continued risks of active symptoms and/or need for corticosteroid
therapies. For example, given the low surgery-discussion rates in our current work, our
findings could under-estimate UC preferences regarding surgery therapy: it is possible
that UC patients may be more willing to accept ostomy surgery; and may even prefer Jpouch surgery to chronic ineffective medical therapy.
We are currently working on an online patient-driven educational tool for UC
patients with a dedicated surgery component. We have also designed a DCE-based
study to evaluate the impact of this tool on UC patient risk tolerances. Rigorous
methodologies to assess the effect of educational interventions on decision-making by
UC patients have not previously been performed, and thus the impact of such
educational interventions is unknown. This information can enhance and validate our
proposed educational tool in UC. It can also set metrics for future educational tools in
UC (or in IBD) as well as establish a rigorous methodology to assess efficacy and impact
of future tools in IBD.
Our current work in UC patient risk tolerance assessment also highlights the
need for rigorous assessment of patient preferences. The findings of our DCE study are
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in contrast to the findings from more traditional—but methodologically flawed—systems
for assessing patient risk preferences. However, DCE is not without potential limitations
including one inherent to its approach, namely that it remains a simulated decisionmaking experiment. Patients may be more or less likely to accept risks in actual clinical
settings. Revealed-preference (RP) is a method of obtaining measured utilities based
upon actual decision-behaviors. However, because RP data is based on actual choices,
large numbers of observations are needed and data quality is limited: data only reflects
existing therapy options, and may reflect mixed preferences including those of patient,
physician and payer.
While many studies have shown good concordance between DCE and RP
measured risk preferences and the successful ability to merge these data in
transportation and environmental research,162-165 to date only one study has evaluated
such joint estimation in health care.166 UC represents a unique opportunity for healthcare based joint DCE-RP data enrichment. Treatment decisions regarding medical
versus surgical therapy are dominated by UC patient preferences regarding surgery.
Understanding external forces that shape these preferences can inform measured
patient preferences. We have currently proposed a study to utilize our existing I3
database to combine DCE with RP decisions made in real clinical settings. This joint
estimation of preference choice data will have several significant impacts: this will allow
for real-world statistical discrimination of UC patient risk tolerance; it can allow for the
identification of new attributes affecting UC patients’ risk tolerance; it will allow
refinement of DCE measured tolerances to be reflective of revealed behavior; and it can
inform DCE data-enrichment methodology in other chronic diseases and treatment
preferences. Fundamentally, patient preferences play a key role in their satisfaction and
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willingness to accept and adhere to therapies, which in turn influences clinical outcomes.
Thus, improved methodologies in risk estimation can help answer the question, “Why
are UC patients not having surgery, and what can be done to improve medical and
surgical therapy options for UC patients?”
In summary, we have completed a set of experiments that challenges and
changes the way we view the prognosis of UC, how we measure UC disease activity,
the methodologies used to quantify UC patient risk preferences, and the way we view
treatment algorithms in UC. We have determined all-cause and cause-specific mortality
in UC, and investigated methodological tools used to measure these outcomes. We
have investigated and validated a simple patient-driven tool for assessing UC disease
severity. Finally, we have challenged the traditional view that UC patients wish to avoid
colectomy surgery at all costs as well as the conventional methods used to quantify UC
patient preferences for medical and surgical therapies in UC. Our work has immediate
direct impact for UC patients, providers and health-care administers; and it further
informs many important future research questions regarding UC therapies, treatment
algorithms, and patient decision-making.
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